US20110104799A1 - Multifunctional Alleles - Google Patents

Multifunctional Alleles Download PDF

Info

Publication number
US20110104799A1
US20110104799A1 US12/915,447 US91544710A US2011104799A1 US 20110104799 A1 US20110104799 A1 US 20110104799A1 US 91544710 A US91544710 A US 91544710A US 2011104799 A1 US2011104799 A1 US 2011104799A1
Authority
US
United States
Prior art keywords
recombinase
coin
nsi
orientation
dsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/915,447
Other languages
English (en)
Inventor
Aris N. Economides
Andrew J. Murphy
Peter Matthew Lengyel
Peter H.A. Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to US12/915,447 priority Critical patent/US20110104799A1/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ECONOMIDES, ARIS N., LENGYEL, PETER MATTHEW, YANG, PETER H. A., MURPHY, ANDREW J.
Publication of US20110104799A1 publication Critical patent/US20110104799A1/en
Priority to US13/940,609 priority patent/US10392633B2/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MURPHY, ANDREW J., YANG, PETER H.A., ECONOMIDES, ARIS N., LENGYEL, PETER MATTHEW
Priority to US16/459,236 priority patent/US11319557B2/en
Priority to US17/712,003 priority patent/US20220220510A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Definitions

  • the invention relates to nucleic acid constructs for modifying genomes, including knockout constructs and constructs for placing COINs in a genome.
  • Genetically modified non-human animals are included, e.g., genetically modified mice having genes or nucleic acid elements arrayed with selected recombinase recognition sites that allow for deletion or inversion of the genes or nucleic acid elements to form null alleles, selectable alleles, reporting alleles, and/or conditional alleles in non-human animals, e.g., in mice and rats.
  • knockouts are made by homologously replacing a target gene with another sequence of choice, usually a reporter and a selection cassette, where the latter is preferably flanked by site-specific recombinase sites to empower removal of the selection cassette via the action of the cognate site-specific recombinase.
  • the selection cassette can be subsequently removed either by treating cells with the corresponding cognate recombinase or by breeding mouse progeny to a “deletor” strain.
  • the cognate recombinase is Cre, and what remains in the genome is a single loxP site and the reporter.
  • a related strategy has been traditionally employed to generate conditional-null alleles. This involves flanking part of the gene of interest with site-specific recombinase recognition sites (such as lox for Cre, and FRT for Flp) in a manner such that upon action of the cognate recombinase, the region flanked by the site-specific recombinase recognition sites is deleted and the resulting allele is a null allele.
  • site-specific recombinase recognition sites such as lox for Cre, and FRT for Flp
  • FIG. 1 illustrates use of recombinase recognition sites to simultaneously delete one element (U) and invert another (D).
  • FIG. 2 illustrates an embodiment of a Multifunctional Allele (MFA) allele, shown for a nucleotide sequence of interest (NSI), employing a splice acceptor with splice region and an actuating sequence followed by a polyadenylation (pA) signal, a drug selection cassette (DSC; in a suitable orientation of choice), a COIN, and five pairs of recombinase recognition sites.
  • R1/R1′, R2/R2′, R3/R3′, R4/R4′, and R5/R5′ represent cognate pairs of recombinase recognition sites.
  • FIG. 3 illustrates a conceptual rendering of recombinable units (defined by R1/R1′, R2/R2′, R3/R3′, R4/R4′, and R5/R5′) of an embodiment of an MFA allele that employs an actuating sequence (for simplicity the splice acceptor and splice region preceding the sequence, and polyA signal following the sequence are not shown), a DSC (in a suitable orientation of choice), an NSI, and a COIN.
  • an actuating sequence for simplicity the splice acceptor and splice region preceding the sequence, and polyA signal following the sequence are not shown
  • DSC in a suitable orientation of choice
  • an NSI in a suitable orientation of choice
  • COIN COIN
  • FIG. 4 illustrates a particular embodiment of an MFA with specific recombinase recognition sites for purposes of illustration (top), and generating a “cleaned-up” null allele comprising an actuating sequence that comprises a LacZ sequence, and removing the DSC as well as a the NSI and the COIN element from the initial MFA embodiment using a single recombinase step.
  • the splice acceptor and splice region preceding the LacZ sequence, and the polyA signal following the LacZ sequence are not shown.
  • FIG. 5 illustrates a particular embodiment of an MFA that generates a conditional allele that contains/incorporates a COIN from an MFA using a single recombinase (here, a Flp recombinase first acting on FRT3 sites of the allele embodiment).
  • a single recombinase here, a Flp recombinase first acting on FRT3 sites of the allele embodiment.
  • the splice acceptor and splice region preceding the LacZ sequence, and the polyA signal following the LacZ sequence are not shown.
  • FIG. 6 illustrates an embodiment of an MFA that generates a conditional null allele that contains/incorporates a COIN from an MFA using a single recombinase (here, a Flp recombinase first acting on FRT sites of the allele embodiment).
  • a single recombinase here, a Flp recombinase first acting on FRT sites of the allele embodiment.
  • the splice acceptor and splice region preceding the LacZ sequence, and the polyA signal following the LacZ sequence are not shown.
  • FIG. 7 illustrates an embodiment wherein, following recombinase treatment (Flp exposure as shown in FIG. 5 or FIG. 6 ), the allele is exposed to a second recombinase (Cre), resulting in deletion of the NSI and placement of the COIN in sense orientation for transcription.
  • Re recombinase
  • FIG. 8 illustrates an embodiment wherein, following recombinase treatment (Flp exposure), the allele is exposed to a second recombinase, resulting in inversion of the COIN and the NSI due to (an alternative) placement of a recombinase recognition site for the second recombinase at a position 5′ of the NSI.
  • FIG. 9 illustrates the exon-intron structure of the mouse Hprt1 gene in the region of exons 2 to 4, adapted from the Ensembl mouse genome server (top panel—www.ensembl.org), and the region from exon 2 to exon 4 is expanded in the ECR browser (http://ecrbrowser.dcode.org) to highlight regions of conservation.
  • Exon 3 is highlighted by a dotted oval.
  • the black vertical arrow indicates the point of insertion of the actuating sequence and DSC, whereas the gray arrow indicates the point of insertion of the COIN element, all used to engineer the Hprt1 MFA allele. Note that none of the evolutionarily conserved intronic sequences flanking exon 3 are disrupted in the resulting allele.
  • the dotted parallelogram denotes the region that will become the NSI in the Hprt1 MFA allele.
  • FIG. 10 illustrates an example of an MFA, specifically the MFA for the Hprt1 gene.
  • Exon 3 plus evolutionarily conserved intronic sequences flanking exon 3 (as illustrated in FIG. 9 ) of Hprt1 become the NSI.
  • the NSI is placed into the antisense strand with respect to the direction of transcription of the Hprt1 gene.
  • An actuating sequence—SA-lacZ-polyA—and a DSC are placed upstream of the NSI.
  • the actuating sequence is placed in the sense orientation with respect to the direction of transcription of the Hprt1 gene, effectively acting as a gene-trap element, and abrogating transcription downstream of the actuating sequence.
  • a COIN element is placed downstream of the NSI in the antisense orientation with respect to the direction of transcription of the Hprt1 gene. Neither the COIN element nor the NSI can be incorporated into a productive Hprt1 mRNA and therefore the resulting allele, Hprt1 MFA , is a null allele with a reporter (LacZ).
  • the elements comprising the Hprt1 MFA allele are flanked by site-specific recombinase recognition sites arranged as follows: FRT-actuating sequence-Rox-DSC-FRT3-(LoxP)-(NSI)-(Lox2372)-(FRT)-(FRT3)-(COIN)-(Lox2372)-(LoxP)-Rox, where parenthesis denotes placement in the antisense orientation with respect to the direction of transcription of the Hprt1 gene, or in the case of site-specific recombinase sites opposite orientation with respect to mutually recognized pairs.
  • FIG. 11 illustrates an embodiment of an MFA, showing certain overlapping recombinable units (A) and resulting alleles that are generated by the action of a first recombinase (B) or a second (C) and third (D) recombinase.
  • FIG. 12 illustrates an embodiment of an MFA, showing certain overlapping recombinable units (A) and resulting alleles that are generated by the action of a first recombinase (B) or a second (C) and third (D) recombinase.
  • FIG. 13 illustrates an embodiment of an MFA (A), showing resulting alleles that result from action of a first recombinase that places the NSI in sense orientation (B) and a second recombinase that places the NSI in antisense orientation while placing the COIN in sense orientation (C).
  • FIG. 14 illustrates an embodiment of an MFA (A), showing resulting alleles that result from action of a first recombinase that places the NSI in sense orientation (B) and a second recombinase that places the NSI in antisense orientation while placing the COIN in sense orientation (C).
  • FIG. 15 illustrates another embodiment of an MFA (A), showing resulting alleles that result from action of a first recombinase that places the NSI in sense orientation (B) and a second recombinase that places the NSI in antisense orientation while placing the COIN in sense orientation (C).
  • FIG. 16 illustrates an example of an MFA embodiment, wherein the reporter is a SA(adml)-gtx-LacZ-pA, the DSC is Neo, the NSI is a critical exon (e c ), and the COIN is Gtx-SA-HA-myc3-TM-T2A-GFP-pA (A), placement of the NSI in sense orientation by action of a recombinase while maintaining the COIN in antisense orientation (B), and further excision of the NSI with concomitant placement of the COIN in sense orientation (C); arrows indicate primers used to confirm identities and orientations of recombinase sites in the MFA (A), and upon recombinase treatment (B and C).
  • the reporter is a SA(adml)-gtx-LacZ-pA
  • the DSC is Neo
  • the NSI is a critical exon (e c )
  • the COIN is Gtx
  • FIG. 17 shows the results of cell viability and proliferation assays for Hprt1 + /Y, Hprt1 MFA /Y, Hprt1 COIN /Y, and Hprt1 COIN-INV /Y ES cells respectively, all cultured in standard ES cell culture media either without 6-TG (no 6-TG; upper panels) or supplemented with 10 ⁇ M 6-TG (6-TG; lower panels).
  • FIG. 18 shows Western blots of total protein preparations derived from Hprt1 + /Y cells (WT), Hprt1 MFA /Y (MFA)—i.e. cells targeted with the MFA of FIG. 16A , Hprt1 COIN /Y cells (MFA+FLPo)—i.e. cells targeted with the MFA of FIG. 16A and then treated with FLPo, and Hprt1 COIN-INV /Y cells (MFA+FLPo+Cre)—i.e. Hprt1 COIN /Y cells treated with Cre; the top panel shows detection of Hprt1 protein, the center panel shows detection of LacZ (reporter) protein, and bottom panel shows detection of GAPDH protein as a loading control.
  • WT Hprt1 + /Y cells
  • MFA+FLPo Hprt1 COIN /Y cells
  • MFA+FLPo Hprt1 COIN-INV /Y cells
  • Cre
  • null alleles and conditional alleles are provided.
  • methods and compositions are provided for engineering multifunctional alleles into a genome in a single targeting step.
  • Methods and compositions for knockout complementation analysis in genetically modified nonhuman animals are provided, including methods that comprise a single targeting step.
  • a modified allele comprising a 3′ splice region and splice acceptor, an actuating sequence 3′ with respect to the splice acceptor, and a nucleotide sequence of interest (NSI) 3′ with respect to the actuating sequence, wherein the NSI is in antisense orientation with respect to the target gene (or the locus being modified, or with respect to the actuating sequence).
  • NBI nucleotide sequence of interest
  • the actuating sequence is selected from a microRNA, a transcriptional stop signal (such as a polyadenylation region), a nucleotide sequence encoding a cDNA, or any combinations thereof, and may include regulatory elements such as operators, enhancers, and insulators.
  • the cDNA encodes a reporter (e.g., encodes for LacZ).
  • the actuating sequence comprises an exon. In a specific embodiment, the exon is the 5′-most exon of a locus.
  • the NSI comprises an exon. In one embodiment, the NSI comprises an exon and neighboring intronic sequence. In a specific embodiment, the flanking exon is flanked 5′ and 3′ with intronic sequence. In one embodiment, the nucleotide sequence comprises two or more exons, and in a specific embodiment comprises intronic sequence(s). In another embodiment, the NSI lacks an exon, or lacks a fragment of an exon.
  • the modified allele comprises a COIN.
  • the COIN is 3′ with respect to the NSI; in another embodiment, the COIN is 5′ with respect to the NSI.
  • the COIN is selected from a reporter, a gene trap-like element (GT-like element), and a gene trap-like reporter (GT-like reporter).
  • GT-like element is selected from SA-drug resistance cDNA-polyA.
  • GT-like reporter is selected from SA-reporter-polyA.
  • the COIN comprises a 3′ splice region.
  • the 3′ splice region is followed by a sequence selected from a cDNA, an exon-intron sequence, a microRNA, a microRNA cluster, a small RNA, a codon-skipping element, an IRES, a polyadenylation sequence, or any combination thereof.
  • the small RNA is a mirtron.
  • the codon-skipping element is T2A, E2A, or F2A.
  • the modified allele comprises a drug selection cassette (DSC).
  • DSC drug selection cassette
  • the modified allele is on a targeting construct that comprises an upstream and a downstream homology arm.
  • at least one homology arm is a mouse homology arm.
  • both homology arms are mouse homology arms.
  • the modified allele comprises, from 5′ to 3′, a splice acceptor, an actuating sequence, a DSC, a NSI and a COIN wherein the nucleotide sequence of interest and the COIN are both in antisense orientation with respect to the actuating sequence, and five pairs of site-specific recombinase recognition sites.
  • the modified allele upon exposure to a first site-specific recombinase that independently recognizes and inverts sequence between a first pair of the site-specific recombinase recognition sites and deletes a sequence between a second pair of the site-specific recombinase recognition sites, results in an allele that comprises the NSI in sense orientation for transcription, that lacks the DSC, and that comprises the COIN in antisense orientation.
  • the modified allele comprises third and fourth site-specific recombinase recognition sites arranged such that further exposure of the allele to a second recombinase that independently recognizes the third and fourth site-specific recombinase recognition sites results in deleting the NSI and placing the COIN in sense orientation for transcription.
  • a nucleic acid construct comprises (a) a reporter in sense orientation and a DSC in a suitable orientation of choice, and in antisense orientation a NSI and a COIN; (b) five pairs of site specific recombinase recognition sites, wherein the five pairs of recombinase recognition sites are recognized by no more than three recombinases; wherein upon treatment of the nucleic acid construct with a first recombinase, a modified allele is formed wherein (i) the NSI is placed in sense orientation, (ii) the COIN remains in antisense orientation, (iii) the reporter and the DSC are deleted, and, (iv) the modified allele upon treatment with a second recombinase inverts and/or deletes the NSI and places the COIN in sense orientation.
  • the five pairs of site-specific recombinase recognition sites are FRT3, Rox, FRT, loxP, and lox2372 pairs.
  • the first recombinase is a Flp recombinase
  • the second recombinase is a Cre recombinase
  • the modified allele upon treatment with the second recombinase results in an allele that cannot be deleted or inverted by the first or the second recombinase.
  • the nucleotide sequence of interest is a wild-type exon of a gene.
  • the NSI is an exon of a gene having one or more nucleic acid substitutions, deletions, or additions.
  • the NSI is a wild-type exon plus intronic flanking of a gene. In another embodiment, the NSI is an exon plus neighboring intronic sequence of a gene having one or more nucleic acid substitutions, deletions, or additions.
  • the NSI is a wild type intron of a gene. In another embodiment, the NSI is an intron of a gene having one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon or exons of a gene that comprises one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon of a mammal.
  • the mammal is a human, mouse, monkey, or rat.
  • the COIN comprises a 3′ splice region.
  • the 3′ splice region is followed by a sequence selected from a cDNA, an exon-intron sequence, a microRNA, a microRNA cluster, a small RNA, a codon-skipping element, an IRES, a polyadenylation sequence, and a combination thereof.
  • the small RNA is a mirtron.
  • the codon-skipping element is a T2A.
  • the COIN is selected from a reporter, a gene trap-like element (GT-like element), and a gene trap-like reporter (GT-like reporter).
  • GT-like element is selected from SA-drug resistance cDNA-polyA.
  • GT-like reporter is selected from SA-reporter-polyA.
  • the construct further comprises an upstream and a downstream homology arm.
  • the upstream and the downstream homology arm are mouse or rat homology arms.
  • the homology arms are mouse homology arms and the NSI comprises a human sequence.
  • the human sequence comprises a human exon that is a human homolog of a mouse exon.
  • the reporter is selected from: a fluorescent protein, a luminescent protein, or an enzyme.
  • the reporter is selected from GFP, eGFP, CFP, YFP, eYFP, BFP, eBFP, DsRed, MmGFP, luciferase, LacZ, and alkaline phosphatase.
  • the DSC comprises a sequence that encodes an activity selected from neomycin phosphotransferase (neo r ), hygromycin B phosphotransferase (hyg r ), puromycin-N-acetyltransferase (puro r ), blasticidin S deaminase (bsr r ), xanthine/guanine phosphoribosyl transferase (gpt), nourseothricin acetyltransferase (nat1), and Herpes simplex virus thymidine kinase (HSV-tk).
  • a nucleic acid construct comprises an actuating sequence that comprises a 3′ splice acceptor followed by a reporter in sense orientation, DSC in a suitable orientation of choice, a NSI in antisense orientation, and a COIN in antisense orientation, wherein the actuating sequence and reporter is flanked upstream by a recombinase recognition site R1, a recombinase recognition site R2 is disposed between the reporter and the DSC, a recombinase site R3 is disposed between the DSC and the nucleotide sequence of interest, a recombinase site R4 is disposed between the site R3 and the NSI, a recombinase site R5 is disposed between the NSI and the COIN, a recombinase site R1′ is disposed between site R5 and the COIN, a recombinase site R3′ is disposed between R1′ and the CO
  • the reporter is followed by a polyadenylation region.
  • R1 and R1′ are recognized by a recombinase that recognizes R3 and R3′.
  • R4 and R4′ are recognized by a recombinase that recognizes R5 and R5′.
  • R2 and R2′ are not recognized by any recombinase that recognizes R1/R1′, R3/R3′, R4/R4′, or R5/R5′.
  • R1 and R1′, R3 and R3′, and R2 and R2′ are not recognized by any recombinase that recognizes R4 and R4′, and R5 and R5′.
  • R4 and R4′, R5 and R5′, and R2 and R2′ are not recognized by any recombinase that recognizes R1 and R1′ and R3 and R3′.
  • treatment with a single recombinase results in a nucleic acid construct that lacks the DSC, the NSI, and the COIN.
  • the resulting nucleic acid construct consists essentially of the actuating sequence, R1, and R2 or R2′.
  • R1 is a FRT3 site and R2 (or R2′) is a Rox site.
  • treatment with a single recombinase results in a nucleic acid construct that comprises the actuating sequence in sense orientation but that lacks the DSC, lacks the NSI, and lacks the COIN.
  • R2 and R2′ are Rox sites, and the single recombinase is Dre recombinase.
  • treatment with a single recombinase results in a nucleic acid construct that comprises the NSI in the antisense orientation and the COIN in antisense orientation.
  • the single recombinase is a Flp recombinase
  • R1 and R1′ are a FRT variant sequence that does not cross-react with R3 and R3′ (which are also FRT or FRT variants)
  • R2 and R2′ are Rox sequences
  • R4 and R4′ are loxP or lox variant sequences that do not cross-react with R5 and R5′, wherein R5 and R5′ are lox variant sequences.
  • treatment with a single recombinase results in a nucleic acid construct that comprises the NSI in sense orientation and the COIN in antisense orientation.
  • the single recombinase is a Flp recombinase
  • R1 and R1′ are FRT3 sequences
  • R2 and R2′ are Rox sequences
  • R3 and R3′ are FRT sequences
  • R4 and R4′ are loxP sequences
  • R5 and R5′ are lox2372 sequences.
  • the NSI is a wild type exon of a gene. In another embodiment, the NSI is an exon of a gene having one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon or exons of a gene that comprises one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon of a mammal.
  • the mammal is a human, mouse, monkey, or rat.
  • the construct further comprises a homology arm upstream of the construct (an upstream homology arm) and a homology arm downstream of the construct (a downstream homology arm).
  • the upstream and the downstream homology arm are mouse or rat homology arms.
  • the homology arms are mouse homology arms and the NSI comprises a human sequence.
  • the human sequence comprises a human exon homologous to a mouse exon.
  • the reporter is selected from: a fluorescent protein, a luminescent protein, or an enzyme.
  • the reporter is selected from GFP, eGFP, CFP, YFP, eYFP, BFP, eBFP, DsRed, MmGFP, luciferase, LacZ, and alkaline phosphatase.
  • the DSC comprises a sequence that encodes an activity selected from neomycin phosphotransferase (neo r ), hygromycin B phosphotransferase (hyg r ), puromycin-N-acetyltransferase (puro r ), blasticidin S deaminase (bsr r ), xanthine/guanine phosphoribosyl transferase (gpt), nourseothricin acetyltransferase (nat1), and Herpes simplex virus thymidine kinase (HSV-tk).
  • a nucleic acid construct for modifying a locus comprising a first, second, third, fourth, and fifth overlapping recombinable unit, wherein a recombinable unit includes a pair of cognate site-specific recombinase recognition sites, and wherein (a) the first recombinable unit is framed by recombinase sites R1 and R1′ in opposition orientation (allowing inversion via R1/R1′), wherein between R1 and R1′ are disposed an actuating sequence in sense orientation with respect to direction of transcription of the target gene followed by a recombinase site R2 followed by a DSC in a suitable orientation of choice followed by a recombinase site R3 followed by a recombinase site R4 followed by a NSI in antisense orientation followed by a recombinase site R5; (b) the second recombinable unit is framed by recombinase sites
  • R1/R1′ and R3/R3′ are functional with respect to the same site-specific recombinase, and said same site-specific recombinase is not functional with respect to R4/R4′ and R5/R5′, and R2/R2′.
  • R4/R4′ and R5/R5′ are functional with respect to the same site specific recombinase, and said same site-specific recombinase is not functional with respect to R1/R1′ and R3/R3′, and R2/R2′.
  • R2/R2′ are functional with a recombinase, wherein said recombinase is not functional with respect to any of R1/R1′, R3/R3′, R4/R4′, and R5/R5′.
  • R1/R1′ are FRT, FRT3, loxP, or lox2372 sites.
  • R3/R3′ are FRT, FRT3, loxP, or lox2372 sites.
  • R4/R4′ are FRT, FRT3, loxP, or lox2372 sites.
  • R5/R5′ are FRT, FRT3, loxP, or lox2372 sites.
  • R2/R2′ are Rox sites.
  • R2/R2′ are attPlattB sites.
  • R1/R1′ and R3/R3′ are functional with a Flp recombinase. In another specific embodiment, R1/R1′ and R3/R3′ are functional with a Cre recombinase.
  • R4/R4′ and R5/R5′ are functional with a Cre recombinase.
  • R4/R4′ and R5/R5′ are functional with a Flp recombinase.
  • R2/R2′ are Rox sites that are functional with a Dre recombinase.
  • R2/R2′ are attPlattB sites that are functional with PhiC31 integrase (phiC31 ⁇ int).
  • the reporter is selected from: a fluorescent protein, a luminescent protein, or an enzyme.
  • the reporter is selected from GFP, eGFP, CFP, YFP, eYFP, BFP, eBFP, DsRed, MmGFP, luciferase, LacZ, and Alkaline Phosphatase.
  • the DSC comprises a sequence that encodes an activity selected from neomycin phosphotransferase (neo r ), hygromycin B phosphotransferase (hyg r ), puromycin-N-acetyltransferase (puro r ), blasticidin S deaminase (bsr r ), xanthine/guanine phosphoribosyl transferase (gpt), nourseothricin acetyltransferase (nat1), and Herpes simplex virus thymidine kinase (HSV-tk).
  • the NSI is a wild-type exon of a gene. In another embodiment, the NSI is an exon of a gene having one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon of a gene that comprises one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon of a human, mouse, monkey, or rat.
  • the COIN comprises a 3′ splice region.
  • the 3′ splice region is followed by a sequence selected from a cDNA, an exon-intron sequence, a microRNA, a microRNA cluster, a small RNA, a codon-skipping element, an IRES, a polyadenylation sequence, and a combination thereof.
  • the small RNA is a mirtron.
  • the codon-skipping element is T2A, E2A, or F2A.
  • the COIN is selected from a reporter, a gene trap-like element (GT-like element), and a gene trap-like reporter (GT-like reporter).
  • GT-like element is selected from SA-drug resistance cDNA-polyA.
  • GT-like reporter is selected from SA-reporter-polyA.
  • the construct further comprises a homology arm upstream of the construct (an upstream homology arm) and a homology arm downstream of the construct (a downstream homology arm).
  • the upstream and the downstream homology arm are mouse or rat homology arms.
  • the homology arms are mouse homology arms and the NSI comprises a human sequence.
  • the human sequence comprises a human exon homologous to a mouse exon.
  • a multifunctional allele comprising two or more recombinable units that are recognized by two or more different recombinases, each recombinable unit defined by a pair of compatible recombinase recognition sites that define the boundaries of the recombinable unit.
  • Each recombinable unit comprises one or more internal recombinase recognition sites.
  • the one or more internal recombinase recognition sites are selected such that, upon recombination by a first recombinase of a recombinable unit of the multifunctional allele, the one or more internal recombinase recognition sites within one recombinable unit then pair with one or more internal recombinase units within another recombinable unit to allow for the inversion and/or deletion by the first recombinase of a sequence that straddles two or more recombinable units of the multifunctional allele, wherein the inversion and/or deletion is possible only upon inversion of the one or more internal recombinase recognition sites.
  • the inversion and/or deletion is accompanied by inversion of a further recombinase recognition site of the multifunctional allele, wherein inversion of the further recombinase recognition site allows for the inversion or deletion of an element of the multifunctional allele by a second recombinase.
  • a multifunctional allele comprising: (a) a first, a second, a third, a fourth, and a fifth recombinable unit, wherein each recombinable unit is bounded by compatible recombinase recognition sites and wherein the first recombinable unit overlaps the second recombinable unit, and wherein the third, fourth, and fifth recombinable units are contained within the second recombinable unit; (b) a first recombinable unit comprising a 3′ splice acceptor and splice region operably linked to an actuating sequence, a DSC, and a NSI; (c) a second recombinable unit comprising the DSC, the NSI, and a COIN; (d) a third recombinable unit comprising the NSI; (e) a fourth recombinable unit comprising the NSI and the COIN; (f) a fifth recombinable unit
  • a single recombinase recognizes the first pair of recombinase recognition sites and also deletes the actuating sequence and the drug selection cassette.
  • the second inversion orients a recombination site such that following the inversion a second set of recombinase recognition sites are formed that allow deletion of the NSI and/or inversion of the COIN.
  • a nucleic acid construct comprising a MFA comprising, from 5′ to 3′ with respect to the direction of transcription, a COIN in antisense orientation, a NSI in antisense orientation, a DSC, and a reporter in sense orientation, wherein upon treatment of the MFA with a selected recombinase, the COIN, the NSI, and the DSC are excised and the reporter remains in sense orientation; and wherein upon an alternate treatment with a different selected recombinase, the reporter and the DSC are excised, the COIN remains in antisense orientation, and the NSI is placed in sense orientation, such that upon a further treatment with yet another different selected recombinase, the NSI is excised and the COIN is placed in sense orientation.
  • the MFA comprises a first recombinable unit, a second recombinable unit, and a third recombinable unit, wherein the first recombinable unit overlaps the second and third recombinable units, and wherein the second recombinable unit overlaps the first and third recombinable units.
  • the first recombinable unit comprises a COIN in inverse (antisense) orientation and an NSI in inverse orientation, wherein the recombinable unit is flanked upstream of the COIN and downstream of the NSI by compatible recombinase sites R2 and R2′ oriented to direct a deletion; the second recombinable unit overlaps the first recombinable unit, and the second recombinable unit is recombinable by action of a recombinase on a recombination site upstream of the DSC and a recombination site downstream of the reporter, wherein the recombination sites are oriented to direct an inversion, and wherein the recombination site upstream of the DSC is followed by a sequence comprising the NSI.
  • the MFA comprises, from 5′ to 3′ with respect to orientation on a sense strand, a first recombinase site R1, a second recombinase site R2, a third recombinase site R3, the COIN in antisense orientation, a fourth recombinase site R4, a fifth recombinase site R5, a sixth recombinase site R3′ that is compatible with R3 and oriented to direct a deletion of sequence between R3 and R3′, the NSI in antisense orientation, a seventh recombinase site R2′ that is compatible with R2 and oriented to direct a deletion of sequence between R2 and R2′, an eight recombinase site R4′, a DSC, a ninth recombinase site R1′ that is compatible with R1 and oriented to direct a deletion of sequence between R1 and R1, a reporter in sense orientation, and a ten
  • R1/R1′ are Rox sites
  • R2/R2′ are loxP sites
  • R3/R3′ are lox 2372 sites
  • R4/R4′ are FRT sites
  • R5/R5′ are FRT3 sites.
  • the MFA comprises a placement of recombinase sites and COIN, NSI, DSC, and reporter as shown in FIG. 11 , Panel A.
  • an allele as shown in FIG. 11 Panel B is formed upon exposure to a single recombinase that recognizes R1/R1′.
  • Panel C upon exposure to a single recombinase that recognizes R4/R4′ and R5/R5′, an allele as shown in FIG. 11 , Panel C is formed. In a specific embodiment, upon exposure of the allele of FIG. 11 , Panel C to a further recombinase that recognizes R2/R2′ and R3/R3′, an allele as shown in FIG. 11 , Panel D is formed.
  • a nucleic acid construct comprising a MFA comprising, from 5′ to 3′ with respect to the direction of transcription, a NSI in antisense orientation, a DSC, a reporter in sense orientation, and a COIN in antisense orientation; wherein upon treatment of the MFA with a selected recombinase, the NSI and the DSC are excised, the reporter remains in sense orientation, and the COIN remains in antisense orientation; and wherein upon an alternate treatment with a different selected recombinase, the DSC and the reporter are excised, and the NSI is placed in sense orientation and the COIN is in antisense orientation, and wherein following the alternate treatment with the different selected recombinase, the allele is treated with yet another different selected recombinase resulting in NSI excision and placement of the COIN in sense orientation.
  • the MFA comprises a first recombinable unit, a second recombinable unit, and a third recombinable unit, wherein the first recombinable unit overlaps the second and third recombinable units, and wherein the second recombinable unit overlaps the first and third recombinable units.
  • the first recombinable unit comprises a DSC and a reporter in sense orientation, wherein the recombinable unit is flanked upstream of the DSC by recombination sites R2 followed by R3, and flanked downstream of the reporter by recombinase site R3′ wherein R2/R3′ are oriented to direct an inversion, and wherein the DSC is preceded by R2′ oriented with respect to R2 to direct an inversion; the second recombinable unit is flanked upstream of the antisense NSI by R4 and flanked downstream of the antisense COIN by R4′ wherein R4/R4′ are oriented to direct an excision, and wherein the second recombinable unit includes the DSC and reporter; and the third recombinable unit is flanked upstream by R1 and downstream by R1′, wherein R1/R1′ are oriented to direct an excision, wherein upstream and adjacent to R1′ is the DSC and wherein downstream of
  • the MFA comprises from 5′ to 3′, with respect to the direction of transcription, R1, R2, R3, R4, the NSI in antisense orientation, R5, R2′ wherein R2/R2′ are oriented to direct an inversion, the DSC, R1′ wherein R1/R1′ are oriented to direct an inversion, the reporter gene, R3′ wherein R3/R3′ are oriented to direct an inversion, the COIN in antisense orientation, R5′ wherein R5/R5′ are oriented to direct an excision, and R4′ wherein R4/R4′ are oriented to direct an excision.
  • R1/R1′ are Rox sites
  • R2/R2′ are FRT or FRT3 sites
  • R3/R3′ are FRT or FRT3 sites that are not the same as R2/R2′
  • R4/R4′ are lox2372 sites or loxP sites
  • R5/R5′ are lox2372 sites or loxP sites that are not the same as R4/R4′.
  • the MFA comprises a placement of recombinase sites and COIN, NSI, DSC, and reporter as shown in FIG. 12 , Panel A. Treatment with a selected recombinase results in the allele shown in FIG. 12 , Panel B. Alternate treatment with a different selected recombinase results in the allele shown in FIG. 12 , Panel C. Treatment of the allele of FIG. 12 , Panel C with yet another different recombinase results in the allele shown in FIG. 12 , Panel D.
  • a nucleic acid construct comprising a MFA comprising, from 5′ to 3′ with respect to the direction of transcription, a reporter in sense orientation, a DSC, an NSI in antisense orientation, and a COIN in antisense orientation; whereupon treatment of the MFA with a first selected recombinase, the reporter is excised, the NSI is placed in sense orientation, and the COIN remains in antisense orientation, and wherein the allele comprises recombinase sites that allow for an inversion of sequence that upon treatment with a second selected recombinase would place the COIN in sense orientation and the NSI in antisense orientation.
  • the allele is treated with the second selected recombinase.
  • the COIN signals that the NSI has been placed in antisense orientation following treatment with the second recombinase.
  • the MFA comprises, from 5′ to 3′ with respect to the direction of transcription, a recombinase site R1, a reporter, a second recombinase site R2, a DSC, a third recombinase site R3, an NSI in antisense orientation, a fourth recombinase site R4, a fifth recombinase site R5, a sixth recombinase site R1′ that is compatible with R1 and that is oriented with respect to R1 to direct an inversion, a seventh recombinase site R3′ that is compatible with R3 and that is oriented with respect to R3 to direct an inversion, a COIN in antisense orientation, an eighth recombinase site R5′ that is compatible with R5 and that is oriented with respect to R5 to direct an excision, a ninth recombinase site R4′ that is compatible with R4 and that is oriented with respect to R4 to direct
  • R1/R1′ are FRT3 or FRT sites
  • R2/R2′ are Rox sites
  • R3/R3′ are FRT3 or FRT sites that are different from R1/R1′
  • R4/R4′ are loxP or lox2372 sites
  • R5/R5′ are loxP or lox2372 sites that are different from R4/R4′ sites.
  • the MFA comprises a placement of recombinase sites and COIN, NSI, DSC, and reporter as shown in FIG. 13 , Panel A. Treatment with a selected recombinase results in the allele shown in FIG. 13 , Panel B. Treatment of the allele of FIG. 13 , Panel B with a different recombinase results in the allele shown in FIG. 13 , Panel C.
  • a nucleic acid construct comprising a MFA comprising, from 5′ to 3′ with respect to the direction of transcription, a COIN in antisense orientation, an NSI in antisense orientation, a DSC, and a reporter in sense orientation; whereupon treatment of the MFA with a first selected recombinase, the reporter is excised, the NSI is placed in sense orientation, and the COIN remains in antisense orientation, and wherein the allele comprises recombinase sites that allow for an inversion of sequence that upon treatment with a second selected recombinase would place the COIN in sense orientation and the NSI in antisense orientation.
  • the allele is treated with the second selected recombinase.
  • the COIN signals that the NSI has been placed in antisense orientation following treatment with the second recombinase.
  • the MFA comprises, from 5′ to 3′ with respect to the direction of transcription, a recombinase site R1, a second recombinase site R2, a third recombinase site R3, a COIN in antisense orientation, a fourth recombinase site R4, a fifth recombinase site R5, a sixth recombinase site R3′ that is compatible with R3 and that is oriented with respect to R3 to direct an excision, a seventh recombinase site R2′ that is compatible with R2 and that is oriented with respect to R2 to direct an excision, an NSI in antisense orientation, an eighth recombinase site R4′ that is compatible with R4 and that is oriented with respect to R4 to direct an inversion, a DSC, a ninth recombinase site R1′ that is compatible with R1 and that is oriented with respect to R1 to direct an excision,
  • R1/R1′ are Rox sites sites
  • R2/R2′ are loxP or lox2372 sites
  • R3/R3′ are loxP or lox2372 sites that are different from R2/R2′
  • R4/R4′ are FRT or FRT3 sites
  • R5/R5′ are FRT or FRT3 sites that are different from R4/R4′.
  • the MFA comprises a placement of recombinase sites and COIN, NSI, DSC, and reporter as shown in FIG. 14 , Panel A. Treatment with a selected recombinase results in the allele shown in FIG. 14 , Panel B. Treatment of the allele of FIG. 14 , Panel B with a different recombinase results in the allele shown in FIG. 14 , Panel C.
  • a nucleic acid construct comprising a MFA comprising, from 5′ to 3′ with respect to the direction of transcription, an NSI in antisense orientation, a DSC, a reporter in sense orientation, and a COIN in antisense orientation; whereupon treatment of the MFA with a first selected recombinase, the reporter is excised, the DSC is excised, the NSI is placed in sense orientation, and the COIN remains in antisense orientation, and wherein following treatment with the first selected recombinase the allele comprises recombinase sites that allow for an inversion of sequence that upon treatment with a second selected recombinase would place the COIN in sense orientation and the NSI in antisense orientation.
  • the allele is treated with the second selected recombinase.
  • the COIN signals that the NSI has been placed in antisense orientation following treatment with the second recombinase.
  • the MFA comprises, from 5′ to 3′ with respect to the direction of transcription, a recombinase site R1, a second recombinase site R2, a third recombinase site R3, an NSI in antisense orientation, a fourth recombinase site R4, a fifth recombinase site R5, a sixth recombinase site R2′ that is compatible with R2 and that is oriented with respect to R2 to direct an inversion, a DSC, a seventh recombinase site R1′ that is compatible with R1 and that is oriented with respect to R1 to direct an excision, a reporter in sense orientation, an eighth recombinase site R3′ that is compatible with R3 and that is oriented with respect to R3 to direct an inversion, a COIN in reverse orientation, a ninth recombinase site R5′ that is compatible with R5 and that is oriented with respect to R5 to
  • R1/R1′ are Rox sites
  • R2/R2′ are FRT or FRT3 sites
  • R3/R3′ are FRT or FRT3 sites that are different from R2/R2′
  • R4/R4′ are loxP or lox2372 sites
  • R5/R5′ are loxP or lox2372 sites that are different from R4/R4′.
  • the MFA comprises a placement of recombinase sites and COIN, NSI, DSC, and reporter as shown in FIG. 15 , Panel A. Treatment with a selected recombinase results in the allele shown in FIG. 15 , Panel B. Treatment of the allele of FIG. 15 , Panel B with a different recombinase results in the allele shown in FIG. 15 , Panel C.
  • a multifunctional allele comprising a DSC, a reporter, a COIN, a NSI, and five pairs of recombinase sites arranged among the reporter, the DSC, the COIN, and the NSI, wherein no pair of recombinase sites is identical to any other pair, and wherein a first two pairs of recombinase sites are recognized by the same first recombinase, a second two pairs of recombinase sites are recognized by the same second recombinase, and the fifth pair of recombinase sites are recognized by a third recombinase, wherein the first, second, and third recombinases are not identical, and wherein, with respect to direction of transcription, the MFA comprises (from 5′ to 3′): (a) an actuating sequence (e.g., with reporter) in sense orientation, the DSC in sense or antisense orientation, the NSI in antis
  • the arrangement is as in (a), and the pairs of recombinase sites are arranged such that upon exposure to the third recombinase, the fifth pair of recombinase sites direct an excision of the DSC, the NSI, and the COIN, wherein the reporter is maintained in sense orientation.
  • the arrangement is as in (a), and the pairs of recombinase sites are arranged such that upon exposure to the first recombinase, a modified MFA forms wherein the first two pairs of recombinase sites direct excision of the reporter and excision of the DSC and inversion of the NSI to sense orientation, wherein the COIN is maintained in antisense orientation.
  • the modified MFA comprises the second two pairs of recombinase sites that, upon exposure to the second recombinase, result in an allele wherein the NSI is excised and the COIN is placed in sense orientation.
  • the arrangement is as in (b), and the pairs of recombinase sites are arranged such that upon exposure to the third recombinase, the fifth pair of recombinase sites direct an excision of the COIN, the NSI, and the DSC, wherein the reporter is maintained in sense orientation.
  • the arrangement is as in (b), and the pairs of recombinase sites are arranged such that upon exposure to the first recombinase, a modified MFA forms wherein the first two pairs of recombinase sites direct excision of the DSC and the reporter and direct inversion of the NSI to the sense orientation, wherein the COIN is maintained in antisense orientation.
  • the modified MFA comprises the second two pairs of recombinase sites that, upon exposure to the second recombinase, result in an allele wherein the NSI is excised and the COIN is placed in sense orientation.
  • the arrangement is as in (c), and the pairs of recombinase sites are arranged such that upon exposure to the fifth recombinase, the NSI and the DSC are excised and the reporter and the COIN are maintained in antisense orientation.
  • the arrangement is as in (c), and the pairs or recombinase sites are arranged such that upon exposure to the first recombinase, a modified MFA forms wherein the DSC and the reporter are excised, and the NSI is placed in sense orientation, wherein the COIN is maintained in antisense orientation.
  • the modified MFA comprises the second two pairs of recombinase sites that, upon exposure to the second recombinase, result in an allele wherein the NSI is excised and the COIN is placed in sense orientation.
  • the arrangement is as in (d), and the pairs of recombinase sites are arranged such that upon exposure to the fifth recombinase, the DSC, the NSI, and the COIN are excised and the reporter is maintained in sense orientation.
  • the arrangement is as in (d), and the pairs of recombinase sites are arranged such that upon exposure to the first recombinase, a modified MFA forms wherein the reporter and the DSC are excised, and the NSI is placed in sense orientation, wherein the COIN is maintained in antisense orientation.
  • the modified MFA comprises the second two pairs of recombinase sites that, upon exposure to the second recombinase, result in an allele wherein the COIN is placed in sense orientation and the NSI is placed in antisense orientation.
  • the arrangement is as in (e), and the pairs of recombinase sites are arranged such that upon exposure to the fifth recombinase, the COIN, the NSI, and the DSC are excised and the reporter is maintained in sense orientation.
  • the arrangement is as in (e), and the pairs of recombinase sites are arranged such that upon exposure to the first recombinase, a modified MFA is formed wherein the DSC and the reporter are excised, the NSI is placed in sense orientation, and the COIN is maintained in antisense orientation.
  • the modified MFA comprises the second two pairs of recombinase sites arranged such that, upon exposure to the second recombinase, the NSI is placed in antisense orientation and the COIN is placed in sense orientation.
  • the arrangement is as in (f), and the pairs of recombinase sites are arranged such that upon exposure to the fifth recombinase, the NSI and the DSC are excised, the reporter is maintained in sense orientation, and the COIN is maintained in antisense orientation.
  • the arrangement is as in (f), and the pairs of recombinase sites are arranged such that upon exposure to the fifth recombinase, the NSI and the DSC are excised and the reporter is maintained in sense orientation and the COIN is maintained in antisense orientation.
  • the arrangement is as in (f), and the pairs of recombinase sites are arranged such that upon exposure to the first recombinase, a modified MFA is formed wherein the DSC and the reporter are excised and the NSI is placed in sense orientation and the COIN is maintained in antisense orientation.
  • the modified MFA comprises the second two pairs of recombinase sites arranged such that, upon exposure to the second recombinase, the NSI is placed in antisense orientation and the COIN is placed in sense orientation.
  • a method for making a cell that comprises a construct having a nucleotide sequence of interest in antisense orientation and a COIN in antisense orientation comprising the step of introducing into a genome of a cell an MFA as described herein, identifying the cell comprising the MFA, followed by a step of exposing the genome to a first recombinase, wherein action of the first recombinase on the construct in the genome results in the nucleotide sequence of interest being placed in the sense orientation.
  • the cell is a pluripotent cell, an induced pluripotent cell, a totipotent cell, or an ES cell.
  • the ES cell is a mouse or rat ES cell.
  • the construct is introduced into the cell by homologous recombination. In another embodiment, the construct is randomly integrated into a nucleic acid of the cell. In one embodiment, the nucleic acid of the cell is the cell's genome.
  • the NSI comprises an exon. In one embodiment, the NSI comprises an exon and flanking intronic sequence. In a specific embodiment, the flanking exon is flanked 5′ and 3′ with intronic sequence. In one embodiment, the nucleotide sequence comprises two or more exons, and in a specific embodiment comprises intronic sequence(s). In another embodiment, the NSI lacks an exon, or lacks a fragment of an exon.
  • the NSI is a wild-type exon or exons of a gene. In another embodiment, the NSI is an exon or exons of a gene having one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon of a gene that comprises one or more nucleic acid substitutions, deletions, or additions.
  • the COIN comprises an exon of a human, mouse, monkey, or rat gene.
  • the COIN comprises a 3′ splice region.
  • the 3′ splice region is followed by a sequence selected from a cDNA, an exon-intron sequence, a microRNA, a microRNA cluster, a small RNA, a codon-skipping element, an IRES, a polyadenylation sequence, and a combination thereof.
  • the small RNA is a mirtron.
  • the codon-skipping element is T2A, E2A, or F2A.
  • the COIN is selected from a reporter, a gene trap-like element (GT-like element), and a gene trap-like reporter (GT-like reporter).
  • GT-like element is selected from SA-drug resistance cDNA-polyA.
  • GT-like reporter is selected from SA-reporter-polyA.
  • a method for placing a multifunctional allele in a mouse cell genome comprising a step of introducing into a locus in a mouse cell a targeting construct comprising a first recombinable unit that comprises (a) an actuating sequence (e.g., a nucleotide sequence and/or a reporter); (b) a DSC; (c) a NSI in antisense orientation with respect to the locus; (d) a COIN in antisense orientation with respect to the locus; and, (e) site-specific recombinase recognition sites arranged in recombinable units for deleting the reporter and the DSC, for inverting the NSI back to the sense orientation, and for inverting the COIN and deleting or re-inverting the NSI.
  • an actuating sequence e.g., a nucleotide sequence and/or a reporter
  • a DSC e.g., a DSC
  • a NSI in antis
  • the site-specific recombinase recognition sites are arranged in recombinable units such that the NSI will be re-inverted into the antisense strand and the COIN will be inverted into the sense strand. In another embodiment, the site-specific recombinase recognition sites are arranged in recombinable units such that the NSI will be deleted and the COIN will be inverted into the sense strand.
  • the recombinable units are arranged such that upon exposure of the MFA-modified target locus to a first recombinase, a first recombinable unit comprising the reporter and DSC are deleted and the NSI is placed in the sense orientation with respect to the locus and the COIN is maintained in the antisense orientation, forming a second recombinable unit.
  • the nucleotide sequence of interest in antisense orientation is an exon in the antisense orientation, or an exon flanked by intronic sequence wherein the exon and the intronic sequence are each in antisense orientation.
  • the exon being placed in the antisense orientation is identical to the exon being replaced by the targeting construct.
  • the NSI in antisense orientation is an exon and sequence surrounding the exon.
  • the NSI is two or more exons.
  • the NSI is non-exonic sequence.
  • the second recombinable unit generated by the action of the first recombinase is exposed to a second recombinase, wherein the second recombinase deletes the NSI and places the COIN in the sense orientation.
  • the second recombinable unit generated by the action of the first recombinase is exposed to a second recombinase, wherein the second recombinase places the NSI in antisense orientation and places the COIN in sense orientation.
  • a method for complementation of a knockout comprising introducing into a nonhuman animal an MFA as described herein, wherein the nucleic acid construct comprises a wild-type nucleic acid sequence in antisense orientation and a COIN in the antisense orientation, wherein upon exposure of the nucleic acid construct to a first recombinase the wild-type nucleic acid sequence inverts to sense orientation and is transcribed but the COIN remains in the antisense orientation; and wherein upon exposure to a second recombinase the wild type nucleic acid sequence is excised, or inverted back to the antisense strand, and the COIN inverts to sense orientation.
  • the nonhuman animal is a mouse.
  • the COIN is a reporter element.
  • the reporter element is selected from a fluorescent protein, a luminescent protein, or an enzyme.
  • the reporter is selected from GFP, eGFP, CFP, YFP, eYFP, BFP, eBFP, DsRed, MmGFP, luciferase, LacZ, and Alkaline Phosphatase.
  • a mammalian cell comprising a multifunctional allele in accordance with the invention is provided.
  • the mammalian cell is selected from a mouse cell, and a rat cell.
  • the cell is selected from a stem cell, an embryonic stem (ES) cell, an induced pluripotent cell, a pluripotent cell, and a totipotent cell.
  • ES embryonic stem
  • non-human embryo or non-human animal comprising a multifunctional allele in accordance with the invention is provided.
  • the non-human embryo or non-human animal comprises a multifunctional allele that has been exposed to one or more site-specific recombinases.
  • the multifunctional allele has been exposed to the one or more site-specific recombinases as the result of a breeding step wherein a non-human animal comprising a multifunctional allele has been mated with a non-human animal comprising the one or more site specific recombinases, and the non-human embryo or non-human animal is a progeny of the breeding step.
  • a cell comprising an MFA as described herein is provided, wherein the cell is a mammalian cell, e.g., an ES cell or pluripotent or induced pluripotent cell.
  • the cell is a mouse or rat cell.
  • a non-human animal comprising an MFA as described herein, or an MFA that has been exposed to one or more recombinases as described herein.
  • a non-human embryo comprising an MFA as described herein, or an MFA that has been exposed to one or more recombinases as described herein.
  • a cell, a non-human embryo, or a non-human animal made using an MFA as described herein is provided.
  • a cell, a non-human embryo, or a non-human animal made using an MFA as described herein is provided.
  • any aspect or embodiment can be used in connection with any other aspect or embodiment as appropriate, e.g., any reporter or DSC recited in connection with any particular MFA embodiment can be used with any MFA embodiment described herein, and any particular recombinase or recombinase site mentioned in connection with any particular MFA embodiment can be used with any MFA embodiment described herein.
  • sense orientation refers to the coding direction or sense strand of a transcribable nucleic acid sequence in the local context of the genome, e.g., when a sequence is placed in “sense orientation” in or near a transcribable sequence in a genome, the orientation of the sequence is compatible with transcription and, for protein-coding genes also translation of the sequence in the region or locus or gene in which the sequence is placed.
  • antisense orientation refers to placement of a sequence at a region or locus or gene in which the sequence is in the strand opposite (or antisense) to that which is compatible with transcription.
  • sequence if a sequence is placed in “sense” orientation in a gene, it can generally be transcribed. If a sequence is placed in “antisense” orientation, it generally will not be transcribed.
  • the sequence can be selected or engineered such that transfer from sense to antisense or from antisense to sense would result in transcription from one strand, but not either.
  • COIN includes reference to a conditional element.
  • a conditional element comprises a nucleotide sequence whose expression (or failure to express) is contingent upon the occurrence of an independent event.
  • a coding region that in a sense orientation would either encode a protein or fragment thereof or a non-coding RNA (ncRNA) is placed in antisense orientation flanked on both sides by site-specific recombination sites in opposite orientation.
  • ncRNA non-coding RNA
  • the coding region is not transcribed, because it is placed in the antisense strand with respect to the target gene.
  • the COIN sequence Upon treatment with the cognate site-specific recombinase, the COIN sequence is inverted, and as a result it becomes incorporated into the transcribed message, resulting in expression of the protein or fragment thereof or in the of the ncRNA.
  • incompatible when used to describe two or more recombinase recognition sites, refers to the quality that the two or more recombinase recognition sites cannot be recombined with one another (but the two or more recombinase recognition sites can be recombined with other cognate (e.g., identical) recombinase recognition sites).
  • site-specific recombinases and their cognate recognition sites such as Cre/lox, Dre/Rox, PhiC31 ⁇ int/attP-attB, Flp/FRT
  • DSC post-targeting excision of the DSC (as long as it is flanked by site-specific recombinase recognition sites) but has also enabled the engineering of conditional-null alleles.
  • Conditional-null alleles have been developed wherein the exon-intron region of the target gene—or more frequently a part thereof—is flanked by recombinase recognition sites, rendering the modified allele amenable to conversion to the null state by the action of the cognate recombinase.
  • the advantage of this method over regular knockouts is that the conversion of the modified gene to a knockout can be spatio-temporally controlled by controlling the place (organ, tissue, or cell type), time, and sometimes, also the duration that the cognate recombinase will be active.
  • conditional-null alleles have been engineered as a follow-up to the corresponding simple knockout alleles, mostly in cases where the latter is either embryonic lethal and/or displays a plurality of phenotypes, hence rendering the study of the target gene's function impossible in an adult setting (in the case of embryonic lethality), or hard to interpret in a specific cell type or biological process (in the case where the gene displays a plurality of phenotypes).
  • the FIEx method has been used both for targeting and as a gene trap (GT), but the basic design principles are the same irrespective of the final application.
  • a basic design of a FIEx is shown in FIG. 1 , with U representing, e.g., a DSC and D representing a reporter.
  • the result of recombinase action on the FIEx construct is permanent deletion of the U element (e.g, the DSC) and inversion (and expression) of the D element (e.g., the reporter).
  • FIEx was developed as a method to engineer conditional alleles.
  • FIEx was first used to generate a “conditional-null” allele for Rarg, by inserting the FIEx cassette into this gene such that a loxP/lox511 couplet was inserted upstream of exon 8 of Rarg, and the remainder of the FIEx cassette—composed 5′ to 3′ of SA-lacZ-SV40polyA (a GT-like element) in the antisense orientation with respect to Rarg, and then another loxP/lox511 couplet in the antisense orientation with respect to the first loxP/lox511 couplet, and containing a neomycin phosphotransferase mini gene (neo) in the sense orientation—into intron 8 of Rarg.
  • SA-lacZ-SV40polyA a GT-like element
  • This design empowers Cre-mediated inversion of the GT-like element SA-lacZ-SV40polyA such that it is brought into the sense strand and acts as a gene trap; simultaneously, exon 8 of Rarg is brought into the antisense orientation (effectively ensuring that even in the case where transcription does not terminate at the end of the GT-like element SA-lacZ-SV40polyA, exon 8 will not be incorporated into the read-through message), while neo is simultaneously deleted, and thereby resulting in a null allele of Rarg in which the expression of Rarg is replaced by that of lacZ.
  • the FIEx method has been also adapted for use in gene trapping.
  • a GT element SA- ⁇ geo-polyA, where ⁇ geo is an in-frame fusion of lacZ with neo open reading frames, hence combining the ability to report via LacZ and select via Neo
  • SA- ⁇ geo-polyA SA- ⁇ geo-polyA, where ⁇ geo is an in-frame fusion of lacZ with neo open reading frames, hence combining the ability to report via LacZ and select via Neo
  • two FIEx-like arrays an outer array composed of an FRT/FRT3 couplet
  • an inner array composed of an loxP/lox511 couplet
  • the resulting allele may be a knockout allele or a hypomorphic allele, i.e., one where the expression of the trapped gene is downregulated.
  • Treatment of these FIEx alleles with Flp recombinase should in principle invert the GT element to the anti-sense strand, thereby alleviating transcriptional termination within the trap element, and hence converting the modified gene to conditional GT.
  • This conditional GT now “hidden” in the antisense strand, can be reactivated by exposure to Cre, which will re-invert it by acting on the loxP/lox511 couplets of the FIEx array.
  • KO-first Similar to the FIEx method, typical current KO-first alleles rely at least in part on a GT-like element (either SA-LacZ-polyA or SA- ⁇ geo-polyA) to generate a knockout-like allele.
  • a GT-like element either SA-LacZ-polyA or SA- ⁇ geo-polyA
  • KO-first also requires that the floxed critical exon downstream of the GT-like element must be deleted (using Cre) in order to generate a true null allele.
  • this method first requires placement of a FRT-flanked reporter/GT-like cassette plus a drug mini-gene into an intron of the target gene somewhere upstream of the exon to be deleted, while simultaneously floxing the exon slated to be deleted.
  • This exon has been referred to as the “critical exon”, and irrespective of the criteria that are used to define “critical exon”, the KO-first method clearly requires its removal in order to render the resulting allele a true null. Therefore, following targeting, the resulting allele is neither a true null nor a conditional-null allele.
  • the reasons that the resulting allele is not a true null has been attributed to the fact that without removal of the critical exon (which is floxed) by Cre, there remains the possibility of read-through transcription and splicing around of the GT-like cassette, as well as transcription of the gene's message downstream of the GT-like cassette due to the presence of the drug mini-gene.
  • the reason that the resulting allele is not a conditional-null allele lies in the fact that without removal of both the reporter/GT-like cassette and the drug mini-gene, generation of the normal message (normal composition, as well as level and sites of expression) cannot take place.
  • null or conditional-null—KO-first alleles must be subjected to a second post-targeting step.
  • the KO-first allele must be treated with Cre recombinase to delete the critical exon (which is floxed).
  • conditional allele can be generated after a Flp-mediated removal of the reporter/GT-like cassette and the drug mini-gene, which are together flanked by FRT sites. In this manner, the only modifications that remain are an FRT site and the floxed “critical” exon. This allele in turn can be converted to null by Cre-mediated removal of the floxed exon.
  • KO-first Although the KO-first method addresses some of the limitations of FIEx, it is still hampered by three main drawbacks that limit its utility: first, although it rectifies the lack of reliability of GT-like elements to generate a true KO-first, it fails to provide a true KO-first without an additional post-targeting step; second, due to the criteria used to define “critical exons”, KO-first is limited to protein-coding genes, effectively placing out of reach all the non-protein coding genes (i.e., those that encode ‘non-coding’ RNAs, a class of the very important biomolecules). Furthermore, of the protein-coding genes only those for which a “critical exon” can be defined are amenable to the KO-first design.
  • the criteria for defining a critical exon are that its deletion results in a frame sift between the part of the open reading frame (ORF) preceding it and the part of the ORF following it. This is because induction of this frame shift is obligatory for the KO-first method to provide a definitive knockout. Therefore, even certain classes of protein-coding genes are not amenable to KO-first design. These include genes where the ORF is contained within one exon, and genes where all or the majority of tandem exons leave off in the same frame.
  • knockout-first alleles remove the reporter (e.g., lacZ) together with the DSC using (a step accomplished using Flp recombinased, as the SA-lacZ-polyA and DSC used in KO-first are FRTed) leaving behind only the floxed exon (plus a FRT site upstream of it).
  • the reporter e.g., lacZ
  • the SA-lacZ-polyA and DSC used in KO-first are FRTed
  • a multifunctional allele (MFA) approach permits removal or inactivation of a nucleotide sequence in a genome by introduction of a set of functional elements that comprise an actuating sequence (which confirms removal or inactivation), resulting in a true knockout, and that also contains one or more conditional elements whose expression in the allele is conditional (i.e., dependent on certain molecular events or cues) and reportable.
  • MFA multifunctional allele
  • the MFA approach provides targeting options to generate true knockout-first alleles that do not require a second post-targeting step to convert the targeted alleles to null status, thus providing an advantage and conceptual breakthrough over typical current knockout-first alleles that require a post-targeting step to convert targeted alleles to null alleles.
  • the MFA approach is also not limited to use with “critical exons” and not limited to knockouts by frameshifts, but is generally applicable for modifying any nucleotide sequence of interest. MFAs provide enhanced versatility and a multiplicity of allele options following a single targeting step.
  • the MFA approach provides a true KO-first allele that provides the opportunity for creating a second state in the recipient genome upon inversion of any selected sequence linked with an actuating sequence, and wherein upon inversion transcription of the selected sequence can be reported.
  • the selected sequence can be, e.g., a COIN, which, without limitation, can itself comprise an actuating sequence that, e.g., comprises a repressor to control transcription of another gene or regulatory sequence.
  • a single targeting step placing an MFA at a locus can allow modification of a wild-type locus to a particular state, State A (e.g., a knockout of an endogenous gene).
  • the MFA is designed to enable a change of state to another particular state, State B (e.g., reinstatement of a wild-type phenotype), through the action of a first recombinase.
  • State B can be converted to State C (e.g., reestablishment of the knockout and expression of a COIN) by a second recombinase, and so on.
  • State C e.g., reestablishment of the knockout and expression of a COIN
  • the MFA approach can be used to place an MFA as a gene trap, such that the transgene comprising the MFA obtains expression of MFA elements employing an endogenous transcriptionally active promoter.
  • the MFA approach can be used in traditional transgenesis applications wherein the actuating sequence comprises a promoter, exon, or exons and introns, and optionally transcriptional control elements and followed by a DSC (optional, as it is not necessary for traditional, pronuclear-injection based transgenesis), an NSI (that can be a second actuating sequence) in the antisense orientation with respect to the first actuating sequence, and a COIN (that can be a third actuating sequence) also placed in the antisense orientation with respect to the first actuating sequence.
  • a DSC optionally transcriptional control elements
  • an NSI that can be a second actuating sequence
  • COIN that can be a third actuating sequence
  • the MFA approach provides a multiplicity of options for creating loci that contain null alleles, conditional null alleles, COINs, actuating sequences (which can include reporters) and DSCs, and other elements, in a single targeting step.
  • Post-targeting manipulations of the locus provide options through the use of recombinable units introduced into the MFA-containing locus with the MFA construct in the single targeting step.
  • the number of different recombinases required to exercise the various manipulable options at the locus post-targeting is reduced by employing different pairs of cognate site-specific recombinase recognition sites that are incompatible (e.g., a pair of FRT sites and a pair of FRT3 sites, a pair of loxP sites and a pair of lox2372 sites, etc.).
  • exposure of an MFA-containing locus to a single recombinase can independently act on at least two different recombinable units, to recombine a unit such that the unit places elements of interest (e.g., reporters, DSCs, exons, COINs, etc.) in desired orientations, as well as re-orienting site-specific recombinase recognition sites within the recombinable unit to form new recombinable units.
  • elements of interest e.g., reporters, DSCs, exons, COINs, etc.
  • the MFA approach provides an option for a COIN that can contain any desired sequence, including but not limited to a reporter, or a cDNA encoding a mutant or variant form of the target gene or part of the target gene, or relatives and homologs of the target gene, or even non-protein coding sequences such as microRNAs or clusters of microRNAs, or any combinations of these elements (as they can be accommodated by the placement of internal ribosome entry sites or “self-cleaving” peptides—depending on the choice of elements—between the different elements).
  • the MFA approach provides an option wherein knockout is achieved by targeting, a first recombinase is employed to reestablish the knocked out element back into an active (wild type) state, and a second recombinase is employed to reestablish the knockout, wherein a COIN is placed in sense orientation concomitant with reestablishment or knock-in of the knocked out element, thus reporting the reestablishment of the knockout in the cells where the second recombinase has been activated.
  • the MFA approach provides an option for a reporting element (e.g., a COIN, see FIG. 5 and FIG. 6 , at bottom; detectable by genotyping and/or by visualization or other qualitative or quantitative determination, optionally at the cell level) that, upon action of a second recombinase inverts or inverts and excises a nucleotide sequence of interest (e.g., an exon and surrounding sequence, NSI in FIG. 5 and FIG. 6 ) and places the reporting element in sense orientation, effectively reporting the inversion and/or excision of the NSI.
  • a reporting element e.g., a COIN, see FIG. 5 and FIG. 6 , at bottom; detectable by genotyping and/or by visualization or other qualitative or quantitative determination, optionally at the cell level
  • a second recombinase inverts or inverts and excises a nucleotide sequence of interest (e.g., an exon and surrounding sequence, NSI in FIG. 5 and
  • a null allele following a single targeting step is converted, by a first recombinase to a restored allele (in this embodiment, NSI of FIG. 5 and FIG. 6 is an exon and surrounding sequence or gene or part thereof replaced by the targeting vector), and by a second recombinase to a null allele that reports its presence by placement of the COIN in sense orientation.
  • the MFA approach provides an option for assessing a phenotypic effect of a knockout (following the targeting step), then exposing to a first recombinase to re-establish the knocked out exon or gene or region thereof, assessing the phenotypic effect of the reestablishment—i.e., conversion back to wild type (a step equivalent to a complementation assay but devoid of the requirement of generating a new transgenic mouse line, a requirement which has traditionally accompanied complementation analysis), then optionally exposing to the second recombinase to reestablish the knockout and assessing the phenotypic effect of reestablishing the null allele.
  • the MFA allele combines a true knockout-first approach with the versatility of additional (conditional) elements, and the ability to conduct a true complementation-type analysis in a genetically modified animal in a protocol that comprises a single targeting step.
  • a method for a complementation assay comprising targeting an endogenous allele of a cell with an MFA in accordance with the invention, then in a post-targeting step, generating a conditional-null allele from the MFA (by exposure to a first recombinase), wherein the nucleotide sequence of interest in the MFA comprises an exon or an exon plus surrounding sequence, or another region of interest (associated with, e.g., a phenotype) in the sense orientation, and assessing a phenotypic effect of the conditional-null allele (which should be wild type).
  • the MFA is further exposed to a second recombinase that reestablishes nuliness, and optionally a phenoypic effect is again measured.
  • the second recombinase also places a conditional reporter (e.g., a COIN) in the sense orientation, wherein the conditional reporter reports conversion of the conditional-null allele to a null allele or, as the case may be, reports the reestablishement of nuliness.
  • a conditional reporter e.g., a COIN
  • the NSI comprises an exon and neighboring intronic sequence, or an exon-intron region of a target gene. In another embodiment, the NSI comprises a region encoding an ncRNA, microRNA, microRNA cluster, or other small ncRNA(s).
  • MFAs are alleles that can be placed randomly or targeted at a locus of choice in a genome.
  • the MFA is engineered to produce null, conditional, or combination conditional/null alleles by a judicious placement of the sequences among an array of pairs of cognate site-specific recombinase recognition sites.
  • Resulting alleles produced by the placement of constructs in a genome are manipulable by selected recombinases, which can be introduced to the construct in the genome transiently or through breeding of an animal comprising the construct in its genome with an animal comprising a gene for a selected recombinase (e.g., a Cre-, Flp-, or PhiC31 ⁇ int-expressing strain).
  • a selected recombinase e.g., a Cre-, Flp-, or PhiC31 ⁇ int-expressing strain.
  • methods and compositions are provided for generating a true knockout-first allele where nullness does not depend upon carrying out a second step such as, e.g., removing a “critical exon,” or “critical region,” by the action of a recombinase. Accordingly, embodiments are provided for generating in a single targeting step an allele that is multifunctional, in that it is a true knockout-first allele with a reporter, achieved in a single targeting recombination step.
  • the methods and compositions for generating knockout alleles by the MFA approach are not limited by a requirement to generate a frameshift via deletion of inversion of a critical exon to generate a null allele, as required by some types of knockout alleles (e.g., KO-first or some embodiments of FIEx). Instead, the MFA method relies on its ability to remove the NSI from the transcriptional unit of the target gene at the time of targeting, while simultaneously replacing the expression of the NSI with that of an actuating sequence.
  • the actuating sequence can comprise a GT-like element (e.g., a reporter such as SA-lacZ-polyA), a cDNA, an exon or exons, regulatory elements (e.g., enhancers, insulators, operators). Since the actuating sequence is experimenter-defined, alleles other than null can equally well be rendered. For example, the actuating sequence may encode for a dominant-negative or a constitutively active or an activated form of a gene.
  • a GT-like element e.g., a reporter such as SA-lacZ-polyA
  • a cDNA e.g., a promoters, insulators, operators.
  • regulatory elements e.g., enhancers, insulators, operators
  • the MFA comprises a nucleotide sequence of interest and a COIN that are each in antisense orientation in the resulting allele, and further comprising an actuating sequence and/or a DSC both in sense orientation in the allele (or in sense and antisense orientations, or each independently in sense or antisense orientation), whereupon following exposure to a first recombinase the actuating sequence and/or DSC are deleted, the nucleotide sequence of interest is inverted to a sense orientation, and the COIN is maintained in the antisense orientation.
  • the allele further comprises recombination sites positioned so as to allow for subsequent simultaneous inversion by a second recombinase of the nucleotide sequence of interest and the COIN, such that upon action of the second recombinase the nucleotide sequence of interest is placed in antisense orientation and the COIN is placed in sense orientation.
  • the nucleotide of interest is deleted upon treatment with the second recombinase, leaving the COIN in sense orientation.
  • the COIN is a reporter or a DSC.
  • nucleotide of interest is an exon or region of interest of a gene of one specie (e.g., mouse, rat, non-human primate, or human exon) and the COIN is an exon of a gene of another specie (e.g., a mouse, rat, non-human primate, or human exon).
  • one specie e.g., mouse, rat, non-human primate, or human exon
  • the COIN is an exon of a gene of another specie (e.g., a mouse, rat, non-human primate, or human exon).
  • the MFA approach also allows for a gene trap approach.
  • an MFA is inserted at a transcriptionally active locus. This may be achieved by random recombination, or by “targeted trapping” (see, e.g., U.S. Pat. No. 7,473,557, hereby incorporated by reference).
  • An actuating sequence preceded by a splice acceptor and splice region and followed by a polyA signal affords a knockout or “knockdown” of any existing transcribed genomic sequence.
  • Inclusion of a promoterless DSC i.e. one whose expression is dependent on insertion within the sense strand of a transcriptionally active locus, assures positive selection of cells containing the MFA.
  • NSSI nucleotide sequence of interest
  • COIN nucleotide sequence of interest
  • a COIN in antisense orientation
  • a recommended arrangement of site-specific recombinase recognition sites affords the ability to conditionally express the NSI (from the promoter of the trapped locus), upon exposure to a first recombinase. Then, upon exposure to a second recombinase, the expression of the NSI can be turned off and simultaneously replaced by that of the COIN.
  • the promoterless DSC will ensure that any cell selected will have the ability to express the promoterless NSI and the promoterless COIN, and that expression will be in accordance with the endogenous pattern of expression from the transcriptionally active locus.
  • MFAs are conveniently described in connection with particular embodiments (i.e., with reference to alleles comprising specific named recombinase sites and nucleotide sequences as shown in the figures) for convenience and not by way of limitation, i.e., suitable recombinases and recombinase recognition sites, actuating sequences, reporters, DSCs, and nucleotide sequences of interest can be routinely chosen based upon the disclosure herein.
  • nucleotide sequence of interest can be any nucleotide sequence of interest, e.g., an exon, an exon plus flanking sequence(s), two or more exons, a fragment of a coding sequence, an entire coding sequence, a regulatory element or sequence, an non-protein coding sequence, an intron, or any combinations thereof, etc.
  • COINs can comprise cDNAs as well as non-protein coding sequences and may incorporate elements such as polyadenylation signals and sites, microRNAs or other non-protein coding RNAs, IRESs, codon-skipping peptides, and any combination thereof. Certain COINs and some systems for using them can be found, e.g., in U.S. Pat. No. 7,205,148.
  • Methods and compositions for making and using MFAs in any cell including non-human animal cells, and in non-human animals, are provided.
  • the methods and compositions can be employed using homologous recombination (or random integration) to place useful alleles at any selected site (or random site) in the genome of a cell.
  • the methods and compositions can be used in pluripotent, induced pluripotent, and totipotent cells.
  • Suitable cells for use with the methods and compositions include ES cells, e.g., mouse or rat ES cells.
  • true KO-first alleles are provided that afford an option for a conditional functionality with an embedded reporter function.
  • FIG. 2 An example of how an arrangement of elements and recombinase recognition sites can be designed to create a construct that will ablate the function of the target gene (i.e., create a null allele), or alter the function of the target gene (e.g. turning it into a dominant-negative, constitutively active, or hypomorphic allele), while at the same time embed all the downstream elements that will allow (a) the generation of a conditional allele, and (b) it reversion to a null with a reporter, is illustrated in FIG. 2 .
  • FIG. 2 shows an embodiment of an MFA that can be placed into a genome (e.g., using homology arms to the left and right of the MFA shown).
  • the resulting allele can be converted to a conditional allele, which is accomplished by deleting a first selected sequence and inverting a second selected sequence.
  • the deletion and inversion can be achieved by the same recombinase or a different recombinase.
  • two pairs of incompatible Flp recognition sites can be used—one to direct deletion and the other to direct inversion.
  • two such Flp sites are FRT sites and FRT3 sites.
  • two pairs of incompatible Cre sites can be used, e.g., loxP and lox2372—one to direct deletion and the other to direct inversion.
  • two different recombinases can be used (e.g., a pair of loxP sites with Cre and a pair of FRT sites with Flp). Any suitable sites can be chosen for this embodiment, so long as the sites can direct deletion and inversion of recombinase site pairs of the MFA shown in FIG. 2 (specific embodiments of which are shown in FIG. 5 and FIG. 6 ).
  • construct design of FIG. 2 can be used with any sequences of interest (i.e., NSI is any sequence of interest), the construct design can be particularly useful to replace an exon of interest with a modified exon.
  • NSI is a naturally occurring exon (or exons), and the COIN is a modified exon (e.g., an exon comprising a mutation).
  • the MFA is placed into a genome of, e.g., a mouse ES cell by, e.g., homologous recombination (using appropriate mouse homology arms), and the ES cell is employed to make a genetically modified mouse that comprises the construct in the mouse germline.
  • change of state from the naturally occurring exon to the modified exon is achieved by the action of a recombinase on the MFA.
  • the construct is placed in a genome of, e.g., a mouse, and the mouse either further comprises a recombinase (e.g., Cre) whose activity can be regulated.
  • a recombinase can be regulated by, e.g., employing a fusion protein placing the recombinase under control of an effector or metabolite (e.g., CreER T2 , whose activity is positively controlled by tamoxifen), placing the recombinase under control of a tissue-specific promoter, or placing the recombinase under control of a promoter (or other regulatory element) that is active at a particular developmental stage (e.g., a Nanog promoter), or an inducible promoter (e.g., one whose activity is controlled by doxycycline and TetR or TetR variants), or combinations of these technologies.
  • an effector or metabolite e.g., CreER T2
  • the MFA embodiment shown in FIG. 2 bears elements comprising a sequence encoding an actuating sequence, a DSC, a nucleotide sequence of interest (NSI), and a COIN, wherein the elements are arranged among an array of recombinase recognition sites that are selected so as to provide a desired functionality to the MFA.
  • elements comprising a sequence encoding an actuating sequence, a DSC, a nucleotide sequence of interest (NSI), and a COIN, wherein the elements are arranged among an array of recombinase recognition sites that are selected so as to provide a desired functionality to the MFA.
  • FIG. 2 illustrates a nucleotide sequence of interest (NSI) in a genome of choice (e.g., an NSI in a mouse genome).
  • An MFA as shown is introduced into the genome by, e.g., homologous recombination to replace the NSI.
  • the NSI is replaced with the MFA shown, where the NSI of the MFA is inverted as shown and thus no longer incorporated into the transcript of the target gene.
  • the presence of the MFA can be conveniently confirmed if the actuating sequence contains a reporter (e.g., a lacZ).
  • a DSC is present as well, to assist in selecting modified cells (e.g., mouse ES cells modified with the MFA).
  • the MFA embodiment of FIG. 2 comprises five distinct units of sequence, defined by five sets of recombinase recognition sites.
  • FIG. 3 contains a conceptual rendering of the five distinct units of sequence flanked by compatible recombinase recognition sites.
  • the first distinct recombinable unit comprises R1/R1′ sites (e.g., FRT3 sites) in opposite orientation (i.e., directing an inversion), wherein between the R1/R1′ sites the following are arranged: an actuating sequence (a 3′ splice region and acceptor 5′ with respect to the actuating sequence, and a polyA signal 3′ with respect to the actuating sequence, are not shown in FIG.
  • an R2 site e.g., a Rox site
  • a DSC e.g., a DSC
  • an R3 site e.g., a FRT site
  • an R4 site e.g., a loxP site
  • a nucleotide sequence of interest (NSI) in antisense orientation with respect to direction of transcription (i.e., encoded by the antisense strand) of the target gene
  • an R5 site e.g., a lox2372 site
  • a further sequence includes a COIN placed on the antisense strand and followed by a R4′ site (e.g., loxP site) that is in opposite orientation with respect to the R4 site of the unit, such that upon exposure to a recombinase that recognizes R4/R4′ (e.g., Cre), the COIN is inverted such that the coding sequence of the COIN is now in position for transcription downstream of the NSI.
  • a R4′ site e.g., loxP site
  • the second distinct recombinable unit ( FIG. 3B ) comprises R2/R2′ sites (e.g., Rox sites) in the same orientation (i.e., directing a deletion), comprising the following sequences disposed between the R2/R2′ sites: a DSC, a first R3 site (e.g., a first FRT site) in the same orientation as the R1 site of the first distinct recombinable unit, a first R4 site (e.g., a first loxP site), an NSI in inverted (i.e., antisense) orientation with respect to the target gene, a first R5 site (e.g., a first lox2372 site) in the same orientation with respect to the R4 site, an R1′ site (e.g., a second FRT3 site) and an R3′ site (e.g., a second FRT site) both in opposite orientation as the R3 site, a COIN (in antisense orientation with respect to transcription of the target gene),
  • This second distinct recombinable unit is excisable by a recombinase that recognizes R2/R2′.
  • this unit can be excised to leave behind an actuating sequence (e.g., in some embodiments a reporter, e.g., a sequence encoding lacZ), flanked by an R1 and an R2 or R2′ site.
  • an actuating sequence e.g., in some embodiments a reporter, e.g., a sequence encoding lacZ
  • the third distinct recombinable unit ( FIG. 3C ) comprises R3/R3′ sites (e.g., FRT sites) in opposite orientation (i.e., directing an inversion), comprising the following sequences disposed between the R3/R3′ sites: an R4 site (e.g., a loxP site), a NSI in inverted (i.e., antisense) orientation with respect to transcription of the target gene, an R5 site (e.g., lox2372 site) in the same orientation as the R4 site of the unit (i.e., of FIG. 3C ), and an R1′ site (e.g., a FRT site) in the opposite orientation as the R3 site.
  • R3/R3′ sites e.g., FRT sites
  • opposite orientation i.e., directing an inversion
  • This unit can be inverted by the action of a recombinase that recognizes R3/R3′ (e.g., a Flp recombinase where R3/R3′ sites are FRT sites), resulting in placement of the NSI in proper orientation for transcription and translation.
  • a recombinase that recognizes R3/R3′ e.g., a Flp recombinase where R3/R3′ sites are FRT sites
  • the fourth distinct recombinable unit ( FIG. 3D ) comprises R4/R4′ sites (e.g., two loxP sites) in the same orientation (i.e., directing a deletion), comprising the following sequences disposed between the R4/R4′ sites: an NSI in inverted (i.e., antisense) orientation, an R5 site (e.g., a first lox2372 site) and an R1′ site (e.g., a FRT3 site) and an R3′ site (e.g., a FRT site) each in the same orientation with respect to the R4 site, a COIN (in antisense orientation), and an R5′ site (e.g., a second lox2372 site) in the same orientation as the R5 site.
  • an NSI in inverted (i.e., antisense) orientation
  • an R5 site e.g., a first lox2372 site
  • R1′ site e.g., a
  • this unit In the presence of a recombinase that recognizes R4/R4′ (e.g., Cre if R4/R4′ are loxP sites, e.g.), this unit is excisable. If placed within the MFA and exposed to the R4/R4′ recombinase (in the absence of exposure to a recombinase that recognizes R1/R1′, R3/R3′), this unit will be deleted and leave behind the actuating sequence (e.g., in some embodiments a reporter, e.g., a sequence encoding lacZ) and the DSC.
  • actuating sequence e.g., in some embodiments a reporter, e.g., a sequence encoding lacZ
  • this unit allows for an embodiment in which the MFA, when replacing a sequence in a genome (e.g., replacing an exon), can act in the presence of a recombinase that recognizes R4/R4′ as a null allele comprising an actuating sequence and a DSC.
  • the DSC of the MFA can be removed, if desired, upon the action of a recombinase that recognizes R2/R2′ (e.g., a Dre recombinase where R2/R2′ are Rox sites) because the DSC would be flanked upstream and downstream with R2/R2′ sites in the same orientation.
  • the fifth distinct recombinable unit ( FIG. 3E ) comprises R5/R5′ sites (e.g., two lox2372 sites) in the same orientation (i.e., directing a deletion) as well as in the same orientation of the R4/R4′ sites of the fourth distinct recombinable unit, comprising the following sequences disposed between the R5 and R5′ sites: an R1′ site (e.g., a FRT3 site) and an R3′ site (e.g., a FRT site) in the same orientation with respect to each other but in opposite orientation to the R1 site of the first distinct recombinable unit, and a COIN (in antisense orientation) with respect to transcription of the target gene.
  • R1′ site e.g., a FRT3 site
  • R3′ site e.g., a FRT site
  • COIN in antisense orientation
  • each recombinable unit comprises site-specific recombination sites within the recombinable unit, and that action of a recombinase on sites (across recombinable units) achieves desired and described manipulations of the MFA that achieve intended functions of the MFA.
  • action of a recombinase that recognizes R1/R1′ and R3/R3′ functions to manipulate portions of all five recombinable units as they are conceptually displayed in FIG. 3 .
  • an MFA Once an MFA is placed at a desired location in a genome it can be engineered such that it provides a null allele with a reporting function, wherein the null allele can be remodified (in post-targeting, recombinase-mediated step) such that it lacks all sequences flanked with recombinase recognition sites oriented in the same direction.
  • An example of this embodiment is shown in FIG. 4 showing examples of suitable recombinase recognition sites, where all elements other than the actuating sequence (here, encoding lacZ) are flanked upstream and downstream by Rox sites. Upon exposure to Dre recombinase, only the actuating sequence is present.
  • An MFA as illustrated in FIG. 2 and as exemplified at the top of FIG. 3 can be used to create a conditional allele.
  • a conditional allele can be generated by selecting the appropriate recombinase with which to expose the allele in the first instance.
  • the appropriate recombinase in this embodiment is a recombinase that inverts the NSI back to the sense strand and leaves the COIN in the antisense orientation.
  • a recombinase that recognizes R1/R1′ and also R3/R3′ e.g., a Flp recombinase where R1/R1′ and R3/R3′ are selected from FRT and FRT3 sites; see FIG. 5 for a particular embodiment.
  • the same conditional allele can be achieved whether Flp-mediated inversion occurs first via FRT sites (as in FIG. 5 ) or FRT3 sites (as in FIG. 6 ).
  • recombinase sites remaining in the allele are selected such that treatment with one or more suitable recombinases results in subsequent deletion of the NSI (or re-inversion of the NSI) and inversion of the COIN, such that the allele results in a null allele with respect to the NSI but also places the COIN in orientation for transcription.
  • An example of this is shown using loxP and lox2372 sites, which each independently direct Cre-mediated recombination. Although Cre-reactive sites are used, any suitable sites can be used instead of Cre sites.
  • the NSI in sense orientation (i.e., in position for transcription and translation) is disposed 3′ with respect to a first lox2372 site.
  • a first loxP site in the same orientation as the first lox2372 site, and an inverted (i.e., antisense) COIN is placed downstream of the first loxP site, and the inverted COIN disposed upstream of a second lox2372 site in opposite orientation with respect to the first lox2372 site.
  • Disposed downstream of the second lox2372 site is a second loxP site disposed in an opposite orientation with respect to the first loxP site.
  • This arrangement allows, upon treatment with Cre, inversion via either lox site followed by deletion via either lox site (see FIG. 7 ).
  • the resulting allele contains a COIN in sense orientation, i.e., in position for transcription and translation.
  • a loxP site is placed 5′ with respect to the NSI (instead of disposed between the NSI and the COIN), such that exposure to Cre results in inversion of the NSI to antisense orientation and the COIN to sense orientation.
  • the arrangement of elements and recombinase sites are as shown in the bottom construct of FIG. 5 or FIG. 6 , wherein the FRT3 site as shown is site R1 that has no cognate site in the resulting allele, the FRT site as shown is a recombinase site R3 that has no cognate site in the resulting allele, the left-most lox2372 site is site R5 that is paired with a cognate recombinase site R5′ occupying the right-most lox2372 site as shown, the left-most loxP site as shown is site R4 that is paired with a cognate recombinase site R4′ provided by the right-most loxP site as shown, and the Rox site as shown is site R2 that has no cognate recombinase site in the resulting allele.
  • the arrangement of elements and recombinase sites of the resulting allele are as shown in the bottom construct of FIG. 7 , wherein the FRT3 site shown is site R1 that has no cognate site in the resulting allele, the lox2372 site is site R5 that is not paired with a cognate recombinase site in the resulting allele, the FRT site shown is site R3 that is not paired with a cognate recombinase site in the resulting allele, the loxP site as shown is site R4 that is not paired with a cognate recombinase site in the resulting allele, and the Rox site as shown is site R2′ that is not paired with a cognate recombinase site in the resulting allele.
  • the resulting allele allows expression of the COIN following exposure to the second recombinase.
  • the COIN is a reporter or a DSC.
  • an MFA comprises a COIN, an NSI, a DSC, a reporter, and recombinase sites that are arranged such that action by one recombinase will excise the COIN, the NSI, and the DSC but not the reporter ( FIG. 11B ), whereas action with a different recombinase will generate an allele that lacks the DSC but that places the NSI in sense orientation while maintaining the COIN in antisense orientation ( FIG. 11C ).
  • This resulting allele has recombinase sites arranged such that action by a further recombinase will excise the NSI and place the COIN in sense orientation ( FIG. 11D ).
  • this MFA will allow selection of a true knockout with a reporter function and removal of the DSC, or placement of an NSI, wherein subsequent removal of the NSI is confirmed by concomitant placement of a COIN in sense orientation.
  • a schematic of some overlapping recombinase units are shown in FIG. 11A for such an allele, with like recombinase units represented by like dashed shapes.
  • an MFA comprises a COIN, an NSI, a DSC, a reporter, and recombinase sites that are arranged such that action by one recombinase will excise the NSI and DSC but maintain the orientation of the reporter and COIN ( FIG. 12B ), whereas action with a different recombinase will generate an allele that lacks the DSC and reporter but that places the NSI in sense orientation while maintaining the COIN in antisense orientation ( FIG. 12C ).
  • This resulting allele has recombinase sites arranged such that action by a further recombinase will excise the NSI and place the COIN in sense orientation ( FIG. 12D ).
  • this MFA will allow selection of a true knockout with a reporter function and removal of the DSC; or placement of an NSI, wherein subsequent removal of the NSI is confirmed by concomitant placement of a COIN in sense orientation.
  • a schematic of some overlapping recombinase units are shown in FIG. 12A for such an allele, with like recombinase units represented by like dashed shapes.
  • an MFA comprises a COIN, an NSI, a DSC, a reporter, and recombinase sites that are arranged such that action by one recombinase will excise the reporter and DSC and place the NSI in sense orientation ( FIG. 13B ).
  • This resulting allele has recombinase sites arranged such that action by a further recombinase will place the NSI in antisense orientation while placing the COIN in sense orientation ( FIG. 13C ).
  • this MFA will allow creation of a conditional allele from an MFA.
  • an MFA comprises a COIN, and NSI, a DSC, a reporter, and a different array of recombinase sites that are arranged such that action by a selected recombinase will excise the reporter and the DSC and place the NSI in sense orientation ( FIG. 14B ).
  • This resulting allele has recombinase sites arranged such that action by a further recombinase will place the NSI in antisense orientation while placing the COIN in sense orientation ( FIG. 14C ).
  • this MFA will also allow creation of a conditional allele from an MFA.
  • an MFA comprises an NSI, a DSC, a reporter, a COIN, and recombinase sites that are arranged such that action by a selected recombinase will excise the reporter and the DSC and place the NSI in sense orientation while maintaining the COIN in antisense orientation ( FIG. 15B ).
  • This resulting allele has recombinase sites arranged such that action by a further recombinase will place the NSI in antisense orientation while placing the COIN in sense orientation ( FIG. 15C ).
  • this MFA will also allow creation of a conditional allele from an MFA.
  • Hprt1 is a gene that is X-linked in mice, and Hprt1-null ES cells are resistant to the nucleobase analog 6-thioguanine (6-TG). This property provides an easy and robust phenotypic test, as cells that are wild type for Hprt1 die in the presence of 6-TG, whereas cells that are null for Hprt1 survive. Additionally, if one targets ES cells that are derived from male blastocysts (as is typically the case, and is also the case for the majority of ES cell lines currently in use for targeting), then only one round of targeting is needed to generate Hprt1 MFA /Y ES cells.
  • an MFA in a targeting vector is prepared by standard genetic engineering methodology and bacterial homologous recombination according to the VELOCIGENE® method described in U.S. Pat. No. 6,586,251 and in Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652-659 (the patent and article are hereby incorporated by reference).
  • the Hprt1 MFA allele is designed around exon 3, defining exon 3 and the conserved intronic sequence directly 5′ and 3′ of it as the NSI ( FIG. 9 ).
  • exon 3 begins in frame 2 (f2) and ends in frame 0 (f0); by extension, the preceding exon (i.e., exon 2) ends in frame 2 (f2), and the following exon (i.e., exon 4) begins in frame 0 (f0).
  • exon 2 is rendered out of frame with respect to exon 4, because exon 2 ends in f2 and exon 4 starts in f0.
  • SA-lacZ-polyA FIG.
  • Hprt1 COIN-INV allele generated by treatment of Hprt1 MFA with FLP or variants of FLP to first generate the Hprt1 COIN allele, then by treatment with Cre to generate Hprt1 COIN-INV ) if there is transcription past the SA-eGFP-polyA of the COIN element ( FIG.
  • the antisense-oriented NSI is exon 3 and surrounding evolutionarily conserved intronic sequence of Hprt1 ( FIG. 9 ), and the antisense-oriented COIN is a SA-eGFP-polyA.
  • the targeting vector has a mouse homology arm upstream of the first FRT3 site and downstream of the second Rox site that direct the targeting into the Hprt1 locus such that it is replaced by its MFA version, whereby (a) a SA-LacZ-polyA element in the sense orientation with respect to the direction of transcription of Hprt1, followed by a DSC in the antisense orientation with respect to the direction of transcription of Hprt1, both preceding exon 3 of Hprt1, (b) exon 3 is placed into the antisense orientation with respect to the direction of transcription of Hprt1, and (c) a COIN element is placed in the antisense orientation with respect to the direction of transcription of Hprt1 downstream of the exon 3, and where these different elements are flanked by site
  • the targeting vector is prepared and electroporated into ES cells according to the VELOCIGENE® method described in U.S. Pat. No. 6,586,251 and in Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652-659 (the patent and article are hereby incorporated by reference).
  • the resulting ES cells bear the MFA allele of Hprt1 in place of the wild type version of Hprt1.
  • the Hprt1 MFA /Y ES cells are resistant to treatment with 6-TG (because they are effectively null for Hprt1), demonstrating the usefulness of the MFA method to generate a true knockout-first allele.
  • Hprt1 SA-LacZ-polyA /Y After treatment with Dre, this property is preserved, while the genotype of the cells is converted to Hprt1 SA-LacZ-polyA /Y. Although for the Hprt1 locus, this modification may neither alter the expression level of the reporter (LacZ) nor have any phenotypic consequences (alter resistance to 6-TG), this may not be the case for other loci.
  • the Hprt1 MFA /Y ES cells are converted to Hprt1 COIN /Y ES cells which are effectively wild type and hence sensitive to 6-TG. In addition, this operation restores expression of the Hprt1 message back to its wild-type identity.
  • Hprt1 COIN /Y ES cells After treatment with Cre, the Hprt1 COIN /Y ES cells are converted to Hprt1 COIN-INV /Y ES cells which are effectively null for Hprt1 and hence resistant to 6-TG.
  • this operation results in abrogation of expression of the wild-type message of Hprt1 message, and its concomitant replacement with a hybrid message composed of the first exon of Hprt1 and eGFP (encoded by the COIN element), thereby generating an allele that expresses eGFP in place of Hprt1.
  • This new property, expression of eGFP can be optionally used to score for inversion of the COIN element to the sense strand, and has further utility in enabling the isolation of cells where this event has taken place from a cell population where both types of cells (Hprt1 COIN /Y ES cells, and Hprt1 COIN-INV /Y ES cells) exist. Therefore, not only is the COIN allele converted into a null, but the event is also marked by a new, easily measurable and useful event.
  • the MFA was electroporated into F1H4 ES cells and were selected for resistance to G418.
  • Hprt1 MFA /Y Five targeted clones (Hprt1 MFA /Y) were obtained from a total of 96 colonies screened. All five of these clones were found to survive and propagate when cultured in standard ES cell media supplemented with 10 ⁇ M 6-TG (which is the standard 6-TG survival assay utilized), as would be expected for cells that are Hprt1-null (Doetschman, T. et al. (1987) Targeted correction of mutant HPRT gene in mouse embryonic stem cells, Nature 330:576-578).
  • Hprt1 MFA allele Upon treatment with recombinase FLPo (Raymond, C. S. and Soriano, P. (2007) High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells, PLoS ONE 2:e162), the Hprt1 MFA allele is converted to the Hprt COIN allele ( FIG. 16B ), giving rise to Hprt1 MFA /Y ES cells. This operation results in removal of the LacZ reporter, the DSC, as well as in re-inversion of the NSI into the sense strand. Therefore, the resulting allele (Hprt1 COIN ) is functionally wild type, as the wild type Hprt1 mRNA is encoded and expressed.
  • Hprt COIN-INV This allele (Hprt COIN-INV ) is functionally null, as the Hprt1 mRNA is replaced by one encoding eGFP (and is also lacking the NSI—i.e., Hprt1's exon 3 and flanking intronic sequences as defined at the design stage).
  • Hprt1 MFA /Y Cells bearing the MFA (Hprt1 MFA /Y) were tested for resistance to the nucleotide analog 6-TG, and were compared with wild-type cells ( FIG. 17 ).
  • Hprt1 MFA /Y ES cells were then treated with FLPo, to test if the Hprt1 MFA allele would be converted to the Hprt1 COIN allele.
  • Hprt1 COIN /Y ES cells are expected to be phenotypically wild type, as Hprt1 expression is restored. This was shown to indeed be the case, as Hprt1 COIN /Y ES cells die when cultured in the presence 6-TG, just like their wild type (Hprt1 + /Y) counterparts. Finally, the Hprt1 COIN /Y ES cells were treated with Cre to generate Hprt1 COIN-INV /Y ES cells, which are predicted to be null for Hprt1 as the COIN module is activated while simultaneously deleting Hprt1's exon 3 ( FIG. 16 , Panel C). When cultured in the presence of 6-TG, the Hprt1 COIN-INV /Y ES cells survived and proliferated, confirming that they are functionally null for Hprt1, as intended by the MFA design and application.
  • Hprt1 COIN /Y ES expression of Hprt1 is restored to wild type levels, reflecting the placement of the NSI (exon 3 of Hprt1) back into the sense orientation, and did not show reporter (LacZ) protein, confirming reporter excision by FLPo.
  • Hprt1 COIN the Hprt1 COIN allele is identical to wild type (Hprt1 + )
  • Hprt1 + the Hprt1 COIN allele is identical to wild type (Hprt1 + )
  • Hprt1 COIN-INV /Y ES cells lack Hprt1 COIN ) protein, effectively confirming the phenotypic observations made using the 6-TG resistance assay. This further confirms that the COIN-based conditional-null allele (Hprt1 COIN ) functions as intended.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/915,447 2009-10-29 2010-10-29 Multifunctional Alleles Abandoned US20110104799A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/915,447 US20110104799A1 (en) 2009-10-29 2010-10-29 Multifunctional Alleles
US13/940,609 US10392633B2 (en) 2009-10-29 2013-07-12 Multifunctional alleles
US16/459,236 US11319557B2 (en) 2009-10-29 2019-07-01 Multifunctional alleles
US17/712,003 US20220220510A1 (en) 2009-10-29 2022-04-01 Methods for modifying a genome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25607809P 2009-10-29 2009-10-29
US12/915,447 US20110104799A1 (en) 2009-10-29 2010-10-29 Multifunctional Alleles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/940,609 Continuation US10392633B2 (en) 2009-10-29 2013-07-12 Multifunctional alleles

Publications (1)

Publication Number Publication Date
US20110104799A1 true US20110104799A1 (en) 2011-05-05

Family

ID=43244777

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/915,447 Abandoned US20110104799A1 (en) 2009-10-29 2010-10-29 Multifunctional Alleles
US13/940,609 Active 2031-08-14 US10392633B2 (en) 2009-10-29 2013-07-12 Multifunctional alleles
US16/459,236 Active 2030-12-27 US11319557B2 (en) 2009-10-29 2019-07-01 Multifunctional alleles
US17/712,003 Pending US20220220510A1 (en) 2009-10-29 2022-04-01 Methods for modifying a genome

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/940,609 Active 2031-08-14 US10392633B2 (en) 2009-10-29 2013-07-12 Multifunctional alleles
US16/459,236 Active 2030-12-27 US11319557B2 (en) 2009-10-29 2019-07-01 Multifunctional alleles
US17/712,003 Pending US20220220510A1 (en) 2009-10-29 2022-04-01 Methods for modifying a genome

Country Status (13)

Country Link
US (4) US20110104799A1 (zh)
EP (2) EP2494047B1 (zh)
JP (3) JP5908405B2 (zh)
CN (2) CN102666854B (zh)
AU (1) AU2010319894B2 (zh)
CA (1) CA2779858C (zh)
CY (2) CY1118659T1 (zh)
DK (2) DK2494047T3 (zh)
ES (2) ES2716981T3 (zh)
PL (2) PL2494047T3 (zh)
PT (2) PT3147362T (zh)
TR (1) TR201903376T4 (zh)
WO (1) WO2011059799A1 (zh)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163394A1 (en) 2012-04-25 2013-10-31 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
WO2015021298A3 (en) * 2013-08-07 2015-04-02 Regeneron Pharmaceuticals, Inc. Lincrna-deficient non-human animals
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
WO2015188109A1 (en) 2014-06-06 2015-12-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
WO2015200805A2 (en) 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
WO2016061374A1 (en) 2014-10-15 2016-04-21 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
WO2016081923A2 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2018023014A1 (en) 2016-07-29 2018-02-01 Regeneron Pharmaceuticals, Inc. Mice comprising mutations resulting in expression of c-truncated fibrillin-1
WO2018136758A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hsd17b13 variants and uses thereof
EP3354732A1 (en) 2014-06-23 2018-08-01 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
WO2019006034A1 (en) 2017-06-27 2019-01-03 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS
EP3456831A1 (en) 2013-04-16 2019-03-20 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
EP3460063A1 (en) 2013-12-11 2019-03-27 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
US10285387B2 (en) 2015-03-16 2019-05-14 Regeneron Pharmaceuticals, Inc. Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
WO2019094735A1 (en) 2017-11-10 2019-05-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising slc30a8 mutation and methods of use
WO2019108983A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
US10392633B2 (en) 2009-10-29 2019-08-27 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
EP3653048A1 (en) 2014-12-19 2020-05-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
WO2020131632A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
WO2020206139A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
WO2020206162A1 (en) 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
WO2020247812A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
WO2021092513A1 (en) 2019-11-08 2021-05-14 Regeneron Pharmaceuticals, Inc. Crispr and aav strategies for x-linked juvenile retinoschisis therapy
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
WO2021158883A1 (en) 2020-02-07 2021-08-12 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
WO2021195079A1 (en) 2020-03-23 2021-09-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
WO2021263146A2 (en) 2020-06-26 2021-12-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
WO2022132666A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2023076944A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy
WO2023108047A1 (en) 2021-12-08 2023-06-15 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2024031053A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9510569B2 (en) * 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
WO2017180669A1 (en) * 2016-04-11 2017-10-19 Applied Stemcell, Inc. Site-specific integration of transgenes
CN107779462B (zh) * 2016-08-29 2021-06-04 中国科学院分子细胞科学卓越创新中心 双同源重组谱系示踪技术
WO2018096356A1 (en) * 2016-11-28 2018-05-31 Horizon Discovery Limited Methods for conditional gene knock-out
MX2020013545A (es) 2018-06-13 2021-02-26 Regeneron Pharma Modelo en roedores de fibrodisplasia osificante progresiva.
AU2020294880B2 (en) * 2019-06-19 2024-05-02 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using Cre mRNA
WO2023220697A1 (en) * 2022-05-12 2023-11-16 Memorial Sloan-Kettering Cancer Center Inducible recombinase systems
JP2024021835A (ja) * 2022-08-04 2024-02-16 株式会社豊田中央研究所 相同組換え方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088353A2 (en) * 2001-04-27 2002-11-07 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof
US20070275466A1 (en) * 2003-06-11 2007-11-29 Economides Aris N Methods of modifying genes in eukaryotic cells
US20090113561A1 (en) * 2004-11-26 2009-04-30 Frankgen Biotechnologie Ag Gene trap cassettes for random and targeted conditional gene inactivation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1092768A1 (en) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Conditional gene trapping construct for the disruption of genes
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002219841A1 (en) * 2000-11-16 2002-05-27 Cornell Research Foundation Inc. Vectors for conditional gene inactivation
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US7582741B2 (en) * 2004-07-26 2009-09-01 University Of Massachusetts Conditional disruption of dicer1 in cell lines and non-human mammals
EP1662005A1 (en) * 2004-11-26 2006-05-31 FrankGen Biotechnologie AG Enhancer-containing gene trap vectors for random and targeted gene trapping
TR201903376T4 (tr) 2009-10-29 2019-04-22 Regeneron Pharma Çok fonksiyonlu alleller.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088353A2 (en) * 2001-04-27 2002-11-07 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof
US20030159160A1 (en) * 2001-04-27 2003-08-21 Pierre Chambon Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
US20040244071A1 (en) * 2001-04-27 2004-12-02 Pierre Chambron Method for stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof
US7074611B2 (en) * 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
US20070275466A1 (en) * 2003-06-11 2007-11-29 Economides Aris N Methods of modifying genes in eukaryotic cells
US20090113561A1 (en) * 2004-11-26 2009-04-30 Frankgen Biotechnologie Ag Gene trap cassettes for random and targeted conditional gene inactivation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cruz et al Transgenic research, 2005, 520-521 *
Raymond et al PLoS ONE 2007, 1: 162e, 1-4 *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319557B2 (en) 2009-10-29 2022-05-03 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
US10392633B2 (en) 2009-10-29 2019-08-27 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
WO2013163394A1 (en) 2012-04-25 2013-10-31 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
US10301646B2 (en) 2012-04-25 2019-05-28 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
US9834786B2 (en) 2012-04-25 2017-12-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
EP3456831A1 (en) 2013-04-16 2019-03-20 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
WO2015021298A3 (en) * 2013-08-07 2015-04-02 Regeneron Pharmaceuticals, Inc. Lincrna-deficient non-human animals
RU2721855C2 (ru) * 2013-08-07 2020-05-25 Регенерон Фармасьютикалз, Инк. Не являющиеся человеком животные с дефицитом дпнрнк
US9554564B2 (en) 2013-08-07 2017-01-31 Regeneron Pharmaceuticals, Inc. IncRNA-knockout mice
CN112715485A (zh) * 2013-08-07 2021-04-30 瑞泽恩制药公司 缺乏lincRNA的非人类动物
US11547100B2 (en) 2013-08-07 2023-01-10 Regeneron Pharmaceuticals, Inc. Method for screening gene expression in lincRNA-deficient mice or rats
IL243581B (en) * 2013-08-07 2022-08-01 Regeneron Pharma Non-human animals with lincrna deficiency
EP4349980A2 (en) 2013-12-11 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
EP3460063A1 (en) 2013-12-11 2019-03-27 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
EP3708671A1 (en) 2014-06-06 2020-09-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
WO2015188109A1 (en) 2014-06-06 2015-12-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
EP3708663A1 (en) 2014-06-23 2020-09-16 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
EP3354732A1 (en) 2014-06-23 2018-08-01 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
EP3461885A1 (en) 2014-06-26 2019-04-03 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
WO2015200805A2 (en) 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
WO2016061374A1 (en) 2014-10-15 2016-04-21 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
EP3561052A1 (en) 2014-10-15 2019-10-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
WO2016081923A2 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
EP3521437A1 (en) 2014-11-21 2019-08-07 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
EP3653048A1 (en) 2014-12-19 2020-05-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
EP3685662A1 (en) 2015-03-16 2020-07-29 Regeneron Pharmaceuticals, Inc. Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
US10285387B2 (en) 2015-03-16 2019-05-14 Regeneron Pharmaceuticals, Inc. Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
EP4368637A2 (en) 2016-05-20 2024-05-15 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2018023014A1 (en) 2016-07-29 2018-02-01 Regeneron Pharmaceuticals, Inc. Mice comprising mutations resulting in expression of c-truncated fibrillin-1
WO2018136758A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hsd17b13 variants and uses thereof
US11696572B2 (en) 2017-06-27 2023-07-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ASGR1 locus
WO2019006034A1 (en) 2017-06-27 2019-01-03 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS
EP4276185A2 (en) 2017-09-29 2023-11-15 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
WO2019094735A1 (en) 2017-11-10 2019-05-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising slc30a8 mutation and methods of use
WO2019108983A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
EP4299732A2 (en) 2017-11-30 2024-01-03 Regeneron Pharmaceuticals, Inc. Rats comprising a humanized trkb locus
WO2020131632A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
WO2020206162A1 (en) 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
WO2020206139A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
WO2020247812A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
WO2021092513A1 (en) 2019-11-08 2021-05-14 Regeneron Pharmaceuticals, Inc. Crispr and aav strategies for x-linked juvenile retinoschisis therapy
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
WO2021158883A1 (en) 2020-02-07 2021-08-12 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
WO2021195079A1 (en) 2020-03-23 2021-09-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
WO2021263146A2 (en) 2020-06-26 2021-12-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
WO2022132666A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
WO2023076944A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2023108047A1 (en) 2021-12-08 2023-06-15 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2024031053A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43

Also Published As

Publication number Publication date
EP3147362B1 (en) 2019-01-02
EP3147362A1 (en) 2017-03-29
AU2010319894B2 (en) 2015-03-05
JP6333316B2 (ja) 2018-05-30
DK3147362T3 (en) 2019-04-08
CN106191126A (zh) 2016-12-07
EP2494047A1 (en) 2012-09-05
ES2716981T3 (es) 2019-06-18
CA2779858C (en) 2019-10-29
DK2494047T3 (en) 2017-04-10
PT2494047T (pt) 2017-02-08
US20220220510A1 (en) 2022-07-14
EP2494047B1 (en) 2017-01-04
US11319557B2 (en) 2022-05-03
AU2010319894A1 (en) 2012-05-31
JP2016063839A (ja) 2016-04-28
CN106191126B (zh) 2020-04-14
TR201903376T4 (tr) 2019-04-22
CY1118659T1 (el) 2017-07-12
ES2613662T3 (es) 2017-05-25
CN102666854A (zh) 2012-09-12
US20130302899A1 (en) 2013-11-14
CN102666854B (zh) 2016-08-24
JP2016185166A (ja) 2016-10-27
JP5908405B2 (ja) 2016-04-26
PT3147362T (pt) 2019-04-02
US10392633B2 (en) 2019-08-27
JP6085696B2 (ja) 2017-02-22
CA2779858A1 (en) 2011-05-19
PL2494047T3 (pl) 2017-05-31
CY1121457T1 (el) 2020-05-29
JP2013509192A (ja) 2013-03-14
WO2011059799A1 (en) 2011-05-19
PL3147362T3 (pl) 2019-06-28
US20190390230A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
US11319557B2 (en) Multifunctional alleles
US20210037799A1 (en) Transgenic animals and methods of use
JP2003512053A (ja) 遺伝子破壊用条件付遺伝子トラッピング構築物
US7473557B2 (en) Method for targeting transcriptionally active loci
JP4359498B2 (ja) 転写活性な座を標的化する方法
US7625755B2 (en) Conditional knockout method for gene trapping and gene targeting using an inducible gene silencer
Xin et al. Gene trap and gene inversion methods for conditional gene inactivation in the mouse
AU2015203003B2 (en) Multifunctional alleles
Wefers et al. Design and generation of gene‐targeting vectors
Anastassiadis Genetic Manipulations of Pluripotent Stem Cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ECONOMIDES, ARIS N.;MURPHY, ANDREW J.;LENGYEL, PETER MATTHEW;AND OTHERS;SIGNING DATES FROM 20101202 TO 20101206;REEL/FRAME:025588/0542

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ECONOMIDES, ARIS N.;MURPHY, ANDREW J.;LENGYEL, PETER MATTHEW;AND OTHERS;SIGNING DATES FROM 20140129 TO 20140320;REEL/FRAME:032789/0801